WO2022076818A1 - Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride - Google Patents

Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride Download PDF

Info

Publication number
WO2022076818A1
WO2022076818A1 PCT/US2021/054171 US2021054171W WO2022076818A1 WO 2022076818 A1 WO2022076818 A1 WO 2022076818A1 US 2021054171 W US2021054171 W US 2021054171W WO 2022076818 A1 WO2022076818 A1 WO 2022076818A1
Authority
WO
WIPO (PCT)
Prior art keywords
dexmedetomidine
pharmaceutically acceptable
subject
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/054171
Other languages
English (en)
French (fr)
Inventor
Frank Yocca
Robert RISINGER
Michael De Vivo
Friso POSTMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxcel Therapeutics Inc
Original Assignee
Bioxcel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Therapeutics Inc filed Critical Bioxcel Therapeutics Inc
Priority to CN202180069020.2A priority Critical patent/CN116615243A/zh
Priority to MX2023003993A priority patent/MX2023003993A/es
Priority to CA3195133A priority patent/CA3195133A1/en
Priority to KR1020237013556A priority patent/KR20230084186A/ko
Priority to JP2023518752A priority patent/JP2023545372A/ja
Priority to EP21878615.0A priority patent/EP4225305A4/en
Priority to IL301971A priority patent/IL301971A/en
Priority to US18/030,405 priority patent/US20240024289A1/en
Priority to AU2021356687A priority patent/AU2021356687A1/en
Publication of WO2022076818A1 publication Critical patent/WO2022076818A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • Bipolar disorder also known as manic depression, manic depressive disorder or bipolar affective disorder, is a psychiatric diagnosis that describes a category of mood disorders defined by the presence of one or more episodes of abnormally elevated mood clinically referred to as mania or, if milder, hypomania. Individuals who experience manic episodes also commonly experience depressive episodes or symptoms, or mixed episodes in which features of both mania and depression are present at the same time.
  • dysphoria The presence of both symptoms of depression and mania simultaneously as well as simply depressive symptoms with irritability is often termed dysphoria or dysphoric mood.
  • a dysphoric mood state is associated with poor outcomes and risk of suicide.
  • dysphoric mood state is associated with a major depressive episode (depression) or bipolar disorder with mixed mood state (symptoms of a major depressive episode with symptoms of mania that do not rise to level that meet criterion for diagnosis of mania).
  • Severe mood disorders can be associated with psychotic symptoms.
  • Major depressive disorder as well as bipolar disorders such as extreme manic episodes can impair one’s normal judgement and sometimes lead to psychotic symptoms such as delusions and hallucinations.
  • Manic episodes typically emerge over a period of days to weeks, but onset within hours is possible, usually in the early morning hours.
  • An untreated episode of either depression or mania can be as short as several weeks or last as long as 8 to 12 months.
  • patients have an unremitting persistent course.
  • Acute manic and mixed episodes are frequently associated with severe behavioral, physical, functional, and cognitive disturbances, all of which can have important personal and social consequences.
  • bipolar mania constitutes a medical emergency requiring a hospital admission to ensure the immediate safety of the patient or others and rapid symptomatic relief (Keck, British Medical Journal, 327 (7422), 1002-3, 2003).
  • Bipolar disorders are characterized by cyclical mood changes, ranging from manic to depressed episodes which, early in the illness, can shift suddenly over the course of days.
  • bipolar disorders are treated by maintaining patients on mood-stabilizing therapy (mainly lithium carbonate or anti-epileptics) combined with adjunctive treatment with antidepressants (tricyclic antidepressants or SSRIs) when patients relapse into a depressive episode, or combined with antipsychotics when patients relapse into a manic episode (Liebermann and Goodwin, Curr. Psychiatry Rep. 2004, 6, 459-465).
  • mood-stabilizing therapy mainly lithium carbonate or anti-epileptics
  • antidepressants tricyclic antidepressants or SSRIs
  • antipsychotics when patients relapse into a manic episode
  • the use of lithium has a number of disadvantages, including the importance of establishing and maintaining an appropriate concentration of lithium in the blood, as well as being associated with a plethora of physiological conditions including hypothyroidism, tremors, dry mouth, weight gain, increased frequency of urination, nausea, impotence, decreased libido, diarrhea, kidney abnormalities, loss of appetite, visual impairment, seizures and arrhythmias.
  • the use of other mainstay drug, valproic acid is associated with hepatic dysfunction. There exists a need to provide an improved therapy in this condition that is devoid of any side-effects.
  • Psychosis is a generic psychiatric term for mental state in which the components of rational thought and perception are severely impaired. Essentially, a psychotic episode involves loss of contact with reality, often manifest as experiencing suspiciousness, anxiety, fearfulness, paranoia, hallucinations and delusions. It is particularly associated with schizophrenia, bipolar disorder (manic depression), Alzheimer’s disease, dementia, Parkinson’s disease, severe clinical depression and substance and/or alcohol abuse. The drugs available to treat psychosis (such as atypical antipsychotics) have limited efficacy and produce extrapyramidal symptoms. [08] This combination of side-effects and limited efficacy of current therapies create a vast unmet need for developing an improved therapeutic treatment for manic episodes, such as for instance manic episodes and psychosis in a subject in need thereof.
  • alpha-2 adrenergic agonist particularly dexmedetomidine or a salt thereof
  • dexmedetomidine or a salt thereof is unexpectedly safe as there are no associated side effects such as tardive dyskinesia and mania that are associated with conventional antipsychotic therapy.
  • dexmedetomidine acts as a mood stabilizer and thereby producing anti-manic and anti-depressant effects in bipolar patients.
  • administration of dexmedetomidine via transmucosal route provides a therapeutic utility in the treatment of said disorders.
  • the present disclosure relates to methods and compositions for treating mania in a subject in need thereof, comprising administering an effective amount of alpha-2 adrenergic agonist or a pharmaceutically acceptable salt thereof to the subject.
  • a method of treating mania associated with a diseased condition in a subject in need thereof comprising administering an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • a method of treating mania associated with neuropsychiatric disorders in a subject in need thereof comprising administering oromucosally (e.g. sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • oromucosally e.g. sublingually or buccally
  • an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • a method of treating mania in a subject in need thereof comprising administering oromucosally (for example, sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • dexmedetomidine is administered to the subject on a daily basis.
  • dexmedetomidine is administered to the subject at night-time on a daily basis.
  • dexmedetomidine is administered to the subject at night-time as a single dose on a daily basis (e.g. once a day).
  • dexmedetomidine is administered to the subject on a daily basis for one to six times a day.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically meaningful cardiovascular effects.
  • the subject is in an agitated state.
  • the subject is in a non-agitated state.
  • a method of treating mania in a subject in need thereof comprising administering oromucosally (for example, sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject wherein said subject is in a non-agitated state.
  • dexmedetomidine is administered to the subject on a daily basis.
  • dexmedetomidine is administered to the subject at night-time on a daily basis.
  • dexmedetomidine is administered to the subject at night-time as a single dose on a daily basis (e.g. once a day).
  • dexmedetomidine is administered to the subject on a daily basis for one to six times a day.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the present disclosure provides an oromucosal composition for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • dexmedetomidine is administered to the subject on a daily basis.
  • the oromucosal composition is selected from the group consisting of a film, patch, lozenge, gel, spray, tablet, liquid drops or the like.
  • the oromucosal composition is film.
  • the composition is a sublingual film.
  • the composition is a buccal film.
  • a method of treating mania in a subject in need thereof comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • dexmedetomidine is administered to the subject on a daily basis.
  • dexmedetomidine is administered to the subject on daily basis one to six times a day.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the subject is agitated.
  • the subject is in a non-agitated state.
  • the subject has dysphoria.
  • the subject has mixed mania, where the bipolar patients (1 or 2) experience some symptoms of mania as well as some symptoms of depression
  • a method of treating mania in a subject in need thereof comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject wherein said subject is in a non-agitated state.
  • dexmedetomidine is administered to the subject on a daily basis.
  • dexmedetomidine is administered to the subject on daily basis for one to six times a day.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the present disclosure provides an intramuscular composition for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • dexmedetomidine is administered to the subject on a daily basis.
  • Bipolar 1 patients with mania have manic episodes that cycle with depression.
  • bipolar 2 patients suffer hypomanic episodes, but both Bipolar 1 and Bipolar 2 tend to cycle into depressive episodes.
  • a diagnostic characteristic of manic and hypomanic mood episodes is the associated sleep disruption. Patients report and experience a decreased need for sleep; often sleeping only a few hours, if at all, at night. Previous approaches have used dexmedetomidine to treat agitation associated with these disorders, and the present disclosure is believed to be the first showing that the underlying disorders can be treated in a non-agitated subject.
  • the methods and compositions disclosed herein can be used as mood stabilizers.
  • Mood stabilizers are medicines that reduce or prevent the highs (mania) and lows (depression) of bipolar disorders.
  • Other mood stabilizers such as lithium and valproic acid are known, and typically are co-administered with anti-psychotics, such as lurasidone.
  • anti-depressants may be administered to bipolar patients. Again, this can enhance or produce, rather than treat mania.
  • dexmedetomidine normalizes depression in the patient.
  • the subjects may also exhibit improved sleep architecture, providing an additional advantageous therapeutic benefit not observed with traditional approaches to treating mania or bipolar disorders.
  • Dexmedetomidine is thus superior to other mood stabilizers because the mania is treated rather than enhanced, depression is alleviated, and the sleep architecture is improved (including increased time spend in restorative deep sleep), which may help prevent episodes of mood alteration (mood stabilization); either elevation (mania, hypomania or mixed mania) or depression (depressive episodes).
  • a method of treating hypomania associated with bipolar disorder II, (also referred to as bipolar disorder 2) in a subject in need thereof comprising administering oromucosally an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • dexmedetomidine is administered to the subject on a daily basis.
  • dexmedetomidine is administered to the subject at night-time on a daily basis (e.g. once a day).
  • dexmedetomidine is administered to the subject at night-time as a single dose on a daily basis.
  • dexmedetomidine is administered to the subject on a daily basis for one to six times a day.
  • the subject is in a non-agitated state.
  • a method of treating bipolar mania in a subject in need thereof comprising administering oromucosally (for example, sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • dexmedetomidine is administered to the subject on a daily basis.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the subject is in a non-agitated state.
  • the subject is in an agitated state.
  • the disclosure provides methods and compositions for treating psychosis in a subject in need thereof, comprising administering an effective amount of alpha-2 adrenergic agonist or a pharmaceutically acceptable salt thereof to the subject.
  • a method of treating psychosis in a subject in need thereof comprising administering an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • a method of treating psychosis in a subject in need thereof comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • dexmedetomidine is administered to the subject on a daily basis.
  • dexmedetomidine is administered to the subject at night-time on a daily basis.
  • dexmedetomidine is administered to the subject at night-time as a single dose on a daily basis. In embodiments, dexmedetomidine is administered to the subject on a daily basis for one to six times a day. In embodiments, the treatment is effective without causing significant sedation. In embodiments, the treatment is effective without experiencing clinically significant cardiovascular effects. In embodiments, the subject is in a non-agitated state
  • the present disclosure provides an oromucosal composition for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the oromucosal composition is selected from the group consisting of a film, patch, lozenge, gel, spray, tablet, liquid drops or the like.
  • the oromucosal composition is film.
  • the composition is a sublingual film.
  • the composition is a buccal film.
  • a method of treating psychosis in a subject in need thereof comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • dexmedetomidine is administered to the subject on a daily basis wherein the subject is in a non-agitated state.
  • dexmedetomidine is administered to the subject on a daily basis for one to six times a day.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the present disclosure provides an intramuscular composition for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the psychosis is acute. In embodiments, the psychosis is chronic. In embodiments, the psychosis is associated with a disease condition such as neuropsychiatric disease or disorder; for example, schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorder (e.g. bipolar I disorder and bipolar II disorder), optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • a disease condition such as neuropsychiatric disease or disorder; for example, schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorder (e.g. bipolar I disorder and bipolar II disorder), optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • the psychosis is associated with diseased condition such as substance abuse disorders (e.g, alcohol, opioid and other substance withdrawal).
  • psychosis is associated with depression.
  • psychosis is associated with schizophrenia.
  • psychosis is associated with bipolar disorder.
  • psychosis is associated with dementia.
  • psychosis is associated with Parkinson’s disease.
  • the subject is in an agitated state. In embodiments, the subject is in a non-agitated state.
  • a method of treating psychosis associated with neuropsychiatric disorders in a subject in need thereof comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject wherein said subject is in a non-agitated state.
  • a method of treating psychosis associated with neurodegenerative disorders in a subject in need thereof comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject wherein said subject is in a non-agitated state.
  • the dosage of dexmedetomidine administered oromucosally may conveniently be in the range of about 2 pg to about 300 pg.
  • suitable dosages include: about 2 pg to about 250 pg, about 2 pg to about 200 pg, about 2 pg to about 190 pg, about 2 pg to about 180 pg, about 3 pg to about 170 pg, about 3 pg to about 160 pg, about 3 pg to about 150 pg, about 4 pg to about 140 pg, about 4 pg to about 120 pg, about 5 pg to about 100 pg, about 5 pg to about 90 pg, about 5 pg to about 85 pg, about 5 pg to about 80 pg, about 5 pg to about 75 pg, about 5 pg to about 70 pg, about 5 pg to about 65 pg, about 5 pg to
  • the dose may be administered one or more times a day.
  • the doses can be administered daily for longer period of time for at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 21 days, at least about 22 days, at least about 23 days, at least about 24 days, at least about 25 days, at least about 26 days, at least about 27 days, at least about 28 days, at least about 29 days, at least about 30 days, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months or at least about one year.
  • the dose is administered for about 2 weeks to about 4 weeks followed by conventional antipsychotic or standard-of-care (SOC).
  • Figure 1 depicts the improvement in YMRS scale in bipolar disorder patients at 24 hours following administration of 180 pg dexmedetomidine hydrochloride sublingual film. Asterisks showed significance versus placebo at 24 hours. *p ⁇ 0.05; ** p ⁇ 0.01 and *** p ⁇ 0.005
  • Figure 2A depicts the Smart-cube signatures of dexmedetomidine hydrochloride (at different doses) similar to antipsychotic drugs.
  • Figure 2B depicts the Smart-cube signatures of two alpha2-adrenergic receptors agonists (guanfacine and clonidine).
  • FTD fronto-temporal dementia
  • Dex or DEX Dexmedetomidine DLB: dementia with Lewy bodies
  • HPC Hydroxypropyl cellulose
  • HPMC hydroxypropyl methylcellulose
  • composition or “pharmaceutical composition” or “formulation” or “composition of the disclosure,” and “composition” are used interchangeably, except where otherwise clearly intended to have different meanings.
  • salt refers to a salt known to be non-toxic and commonly used in the pharmaceutical literature.
  • Typical inorganic acids used to form such salts include hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric, and the like.
  • Salts derived from organic acids, such as aliphatic mono and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxyalkanoic and hydroxyl alkandioic acids, aromatic acids, aliphatic and aromatic sulfonic acids may also be used.
  • a preferred salt is hydrochloride (or dihydrochloride) salt.
  • pharmaceutically acceptable carrier refers to a pharmacologically inert substance to be used as a carrier.
  • carrier and “excipients” are used interchangeably, except where otherwise clearly intended to have different meanings.
  • the term “without significant sedation” and the like means that the patient experiences a level of sedation not greater than Level 3 on the Ramsay Sedation Scale. Level 3 means sedated but responds to commands.
  • the dexmedetomidine may be dosed to achieve a Richmond Agitation Sedation Scale (RASS) of -1 (“light sedation”).
  • RASS Richmond Agitation Sedation Scale
  • an effective amount is interchangeable with “therapeutically effective dose,” or “therapeutically effective amount,” and refers to an amount sufficient to produce the desired effect. An effective amount is sufficient to cause an improvement in a condition of the subject.
  • treat in reference to a particular disease or disorder includes lessening, improving, ameliorating or abrogating the symptoms and/or pathology of the disease or disorder.
  • prevention means preventing the occurrence of a disease, condition, or associated symptoms or preventing the recurrence of the same, for example after a period of improvement.
  • mania refers to a psychological condition that causes a person to experience unreasonable euphoria, very intense moods, hyperactivity, and delusions. Mania (or manic episodes) is a common symptom of bipolar disorder. A different form of mania is called “hypomania” that lasts for a short period (usually a few days). According to DSM-5 criteria, hypomania is distinct from mania in that there is no significant functional impairment; mania, by DSM-5 definition, does include significant functional impairment and may have psychotic features. A patient with mania may also be said to be having a manic episode, which reflect the cyclical nature of the disorder.
  • psychosis refers to a range of conditions that affect the mind, in which there has been some loss of contact with reality.
  • Psychosis is characterized by significant changes in a person’s perceptions, thoughts, beliefs, and behaviors. Symptoms may include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear).
  • Psychosis is a symptom associated with a number of health conditions including the manic phase of bipolar I disorder, as well as schizophrenia, post-traumatic stress disorder (PTSD), and schizoaffective disorder.
  • the term “subject” preferably refers to a human patient.
  • the subject can be any animal, including non-human mammals, such as mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates.
  • Oromucosal means administration to the oral mucosa, specifically the oral cavity and/or the pharynx. Oromucosal administration includes sublingual and buccal routes.
  • sublingual means "under the tongue” and refers to a method of administering substances via the blood vessels under the tongue. Sublingual absorption occurs through the highly vascularized sublingual mucosa, which allows a substance direct access to the blood circulation, thereby providing for direct systemic administration independent of gastrointestinal influences and avoiding undesirable first-pass hepatic metabolism.
  • uccal means administration of the dosage form against the gum and the inner lip or cheek.
  • film herein includes thin films, in any shape, including rectangular, square, or other desired shape.
  • the film may be of any desired thickness and size, such that it can be conveniently placed sub-lingually in the patient.
  • the film may be a thin film having a thickness of from about 20 micrometers to about 200 micrometers or may be a thick film having a thickness of from about 20 micrometers to about 1000 micrometers. In embodiments, the film may have a thickness greater than about 1000 micrometers.
  • dissolvable means the films herein are readily disintegrated, e.g. at least within about 20 minutes, following administration to the oral mucosa. Disintegration is achieved by saliva and/or other aqueous materials on the mucosal surface.
  • mucoadhesion is used herein to refer to adhesion to mucosal membranes, such as those in the oral cavity.
  • mucoadhesive refers to the property of adhering to a mucosal tissue surface in vivo. Such adhesion adherently localizes the dosage form onto the mucus membrane and requires the application of a force to separate the mucoadhesive material from the mucus membrane.
  • neurodegenerative disorders means diseases that feature neurodegeneration and include, but is not limited to, Alzheimer’s disease, frontotemporal dementia (or Pick's disease), Dementia (e.g., Dementia with Lewy bodies, vascular dementia), posttraumatic stress disorder (PTSD), Parkinson's disease, vascular cognitive impairment, Huntington's disease, multiple sclerosis, Creutzfeldt- Jakob disease, multiple system atrophy, progressive supranuclear palsy or Amyotrpohic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease).
  • Alzheimer Alzheimer’s disease
  • Frontotemporal dementia or Pick's disease
  • Dementia e.g., Dementia with Lewy bodies, vascular dementia
  • PTSD posttraumatic stress disorder
  • Parkinson's disease vascular cognitive impairment
  • Huntington's disease multiple sclerosis
  • Creutzfeldt- Jakob disease multiple system atrophy
  • progressive supranuclear palsy progressive supranuclear palsy
  • neuropsychiatric disorders includes, but is not limited to, schizophrenia, bipolar illness (e.g., bipolar disorder 1 or 2), cyclothymia, depression (major depressive episodes in bipolar disorder and in major depressive disorder), and delirium.
  • Opioid or alcohol or substance withdrawal refers to a variety of signs and complaints appearing with the abrupt removal of, or a rapid decrease in the regular dosage of, opioids or alcohol or other drug substances. Physical manifestations may include sweating, nausea, yawning, chills, diarrhea, papillary dilation, piloerection, tachycardia, increased blood pressure, hypersensitivity to pain, stomach cramps, and muscle cramps.
  • water-soluble polymer refers to (i) a polymer that is at least partially soluble in water, and desirably fully or predominantly soluble in water, and/or (ii) a polymer that absorbs water. Polymers that absorb water are referred to herein as water-swellable polymers.
  • the phrase “disposed within a polymer matrix” means that dexmedetomidine or a pharmaceutically acceptable salt thereof is incorporated directly into the polymer solution prior to the formation of the solid polymer matrix film composition.
  • the phrase “deposited on the surface of a polymer matrix” means that dexmedetomidine or a pharmaceutically acceptable salt thereof is formulated as liquid composition separate from the preparation of the solid polymer matrix, and deposited onto the solid polymer, e.g. as one or more micro-deposits, where it dries or is dried.
  • the dried product is sometimes referred to herein as the “micro-deposited matrix film”.
  • the drug liquid formulation may be in any form, including as a solution, emulsion, suspension, or dispersion.
  • unit dose means a physically discrete unit that contains a predetermined quantity of dexmedetomidine or a pharmaceutically acceptable salt thereof.
  • parenteral refers to administration of a drug by injection under one or more layer of skin or mucous membrane, and can include, for example, subcutaneous, intravenous, intraperitoneal or intramuscular injection.
  • cardiovascular effects means herein a lowering in blood pressure (hypotension) and/or heart rate (bradycardia) to the extent that medical intervention is required to address the cardiovascular side effects, where the term “medical intervention” means an intervention that more serious than administering fluids, such as an energy drink.
  • Dexmedetomidine has the IUPAC name (+) 4-(S)-[l-(2,3-dimethylphenyl)ethyl]-lH- imidazole.
  • the monohydrochloride salt it is predominantly used as a medication for the sedation of patients during treatment in an intensive care setting or to sedate patients prior to and/or during surgical and other procedures.
  • Such medication is currently sold under the registered trade name "PRECEDEX”.
  • compositions of dexmedetomidine that may be used herein include generally any suitable salt that has been or may be approved by the US FDA or other appropriate foreign or domestic agency for administration to a human.
  • suitable pharmaceutically acceptable salts include salts of inorganic acids such as hydrochloric, hydrobromic, nitric, carbonic, monohydrocarbonic, phosphoric, monohydrogen phosphoric, dihydrogen phosphoric, sulfuric, hydrogen sulfuric, and hydroiodic acid.
  • salts derived from non-toxic organic acids including acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- toluenesulfonic, citric, tartaric, and methanesulfonic acids, or combinations of these acid salts.
  • Exemplary salts include dexmedetomidine hydrochloride, dexmedetomidine hydrobromide, dexmedetomidine sulfate, dexmedetomidine sulfonate, dexmedetomidine phosphate, dexmedetomidine nitrate, dexmedetomidine formate, dexmedetomidine citrate, dexmedetomidine tartrate, dexmedetomidine malate, dexmedetomidine benzoate, dexmedetomidine salicylate, dexmedetomidine ascorbate or the like.
  • deuterated forms of dexmedetomidine or a pharmaceutically acceptable salt thereof may be included.
  • the dosage of dexmedetomidine or a pharmaceutically acceptable salt thereof is in the range of between about 10 pg to about 405 pg, about 0.5 pg to about 300 pg.
  • suitable dosages include: about 0.5 pg to about 280 pg, about 1 pg to about 270 pg, about 1 pg to about 260 pg, about 1 pg to about 250 pg, about 1 pg to about 240 pg, about 1 pg to about 230 pg, about 1 pg to about 220 pg, about 1 pg to about 210 pg, about 1 pg to about 200 pg, about 1 pg to about 190 pg, about 1 pg to about 180 pg, about 1 pg to about 170 pg, about 1 pg to about 160 pg, about 1 pg to about 150 pg, about 1 pg to about 140 pg, about 1 pg to about
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered oromucosally (e.g. sublingually or buccally at a dose of about 10 pg to about 405 pg, about 10 pg to about 400 pg, about 10 pg to about 350 pg, about 10 pg to about 300 pg, about 10 pg to about 270 pg, about 20 pg to about 240 pg, about 30 pg to about 180 pg, about 40 pg to about 140 pg, about 50 pg to about 120 pg , about 60 pg to about 120 pg, about 70 pg to about 100 pg, about 80 pg to about 100 pg, about 100 pg to about 200 pg, about 120 pg to about 200 pg, or about 120 pg to about 180 pg.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered intramuscularly at a dose of about 10 pg to about 405pg, about 10 pg to about 400 pg, about 10 pg to about 350 pg, about 10 pg to about 300 pg, about 10 pg to about 270 pg, about 20 pg to about 240 pg, about 30 pg to about 180 pg, about 40 pg to about 140 pg, about 50 pg to about 120 pg , about 60 pg to about 120 pg, about 70 pg to about 100 pg, about 80 ⁇ g to about 100 pg, about 100 pg to about 200 pg, about 120 pg to about 200 pg, or about 120 pg to about 180 pg.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered oromucosally (e.g. sublingually or buccally) or intramuscularly at a dose of about (in pg): about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 95, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 205, about 210, about 215, about 220, about 225, about 230, about 235, about 240, about 245 or about 250.
  • the dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered oromucosally (e.g. sublingually or buccally) as a film.
  • the film may be a film described in US Patent No. 10,792,246, which is hereby incorporated by reference in its entirety for all purposes.
  • the film is administered as a single unit dose comprising about 10 pg to about 405 pg or about 100 pg to about 200 pg.
  • each unit contains at least one spot of micro-deposited dexmedetomidine or a pharmaceutically acceptable salt thereof.
  • each unit contains two or more spots of micro-deposited dexmedetomidine or a pharmaceutically acceptable salt thereof.
  • the film may have one micro-deposited spot comprising 120 pg of dexmedetomidine hydrochloride or it may have two micro-deposited spots comprising 60 pg of dexmedetomidine hydrochloride.
  • the film may have one micro-deposited spot comprising 180 pg of dexmedetomidine hydrochloride or it may have two micro-deposited spots comprising 90 pg of dexmedetomidine hydrochloride.
  • one or more unit doses are administered to deliver the total dose.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered oromucosally (e.g. sublingually or buccally) at a dose of about 120 pg to about 405 pg, e.g. about 120 pg to about 270 pg, including about 120 pg and about 180 pg.
  • these doses can be provided via one or more unit dosage forms to deliver the total dose.
  • Suitable doses include (in pg): about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 205, about 210, about 215, about 220, about 225, about 230, about 235, about 240, about 245, about 250, about 255, about 260, about 265, about 270, about 275, about 280, about 285, about 290, about 295, about 300, about 305, about 310, about 315, about 320, about 325, about 330, about 335, about 340, about 345, about 350, about 355, about 360, about 365, about 370, about 375, about 380, about 385, about 390, about 395, about 400 and about 405.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered oromucosally (e.g. sublingually or buccally) at a dose of about 10 pg to about 200 pg, e.g. about 120 pg to about 190 pg.
  • suitable doses include (in pg): about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195 and about 200.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered sublingually at a dose of about 10 pg to about 200 pg, e.g. about 120 pg to about 190 pg.
  • suitable doses include (in pg): about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195 and about 200.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered buccally at a dose of about 10 pg to about 200 pg, e.g. about 120 pg to about 190 pg.
  • Suitable doses include (in pg): about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 205, about 210, about 215, about 220, about 225, about 230, about 235, about 240, about 245, about 250, about 255, about 260, about 265, about 270, about 275, about 280, about 285, about 290, about 295 and about 300.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered intramuscularly at a dose of about 10 pg to about 200 pg, e.g. about 120 pg to about 190 pg.
  • Suitable doses include (in pg): about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, about 160, about 165, about 170, about 175, about 180, about 185, about 190, about 195, about 200, about 200, about 205, about 210, about 215, about 220, about 225, about 230, about 235, about 240, about 245, about 250, about 255, about 260, about 265, about 270, about 275, about 280, about 285, about 290, about 295 and about 300.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in an amount of about 180 pg.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in an amount of about 120 pg.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in an amount of about 90 pg.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in an amount of about 60 pg.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in an amount of about 40 pg.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in an amount of about 30 pg.
  • the dosage of dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered twice a day.
  • the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered at a dose of about 30 pg to about 90 pg during daytime (e.g., 30 pg, 45 pg, 60 pg, or 90 pg) and about 120 pg to about 180 pg during nighttime (e.g., 120 pg or 180 pg).
  • the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered at a dose of about 30 pg to about 90 pg during daytime and 30 pg to about 90 pg during night-time.
  • the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered twice a day at a dose of about 120 pg to about 180 pg during daytime and about 30 pg to about 90 pg during nighttime —In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered as 60 pg per unit dose twice a day to a total dose of 120 pg. For example, a 60 pg unit dose is taken in the morning and another 60 pg unit dose is taken in the evening or nighttime.
  • the exemplary dosage of dexmedetomidine or a pharmaceutically acceptable salt thereof to be administered to a particular patient will depend on the type and extent of the condition, the overall health status of the particular patient, the particular form of dexmedetomidine or a pharmaceutically acceptable salt thereof being administered, and the particular formulation used to treat the patient.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof can be administered to the human subject through various routes, including oromucosal (e.g. sublingual or buccal), oral, parenteral and the like.
  • routes including oromucosal (e.g. sublingual or buccal), oral, parenteral and the like.
  • Formulations suitable for use according to the present disclosure are outlined below. Additional formulations suitable for use according to the present disclosure are described in US 10,792,246, which is hereby incorporated by reference in its entirety for all purposes.
  • Dexmedetomidine or a pharmaceutically acceptable salt thereof can be formulated, according to the present disclosure, into dosage forms suitable for oromucosal administration. Such dosage forms include tablets, powders, pills, films, capsules, liquids, gels, syrups, slurries, suspensions, and the like. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is formulated as a film product.
  • Carriers suitable for inclusion in oromucosal (e.g. sublingual or buccal) formulations include, but are not limited to, sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulphate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, pyrogen - free water and combinations thereof. Carriers which readily dissolve in saliva may be preferred.
  • Oromucosal (e.g. sublingual or buccal) formulations may also include other pharmaceutically acceptable carriers and/or excipients such as binders, lubricants, diluents, coatings, disintegrants, barrier layer components, glidants, colouring agents, solubility enhancers, gelling agents, fillers, proteins, co-factors, emulsifiers, solubilising agents, suspending agents and mixtures thereof.
  • Particular excipients which may be used according to this disclosure, are known in the art, for example as described in Handbook of Pharmaceutical Excipients, fifth edition, 2005 edited by Rowe et al., Megraw Hill.
  • Suitable films for oromucosal (e.g. sublingual or buccal) administration comprise dexmedetomidine or a pharmaceutically acceptable salt thereof either (i) disposed within a polymer matrix or (ii) deposited on the surface of a polymer matrix, e.g., on the surface of a “placebo” film.
  • the polymer component may be one or more water-soluble polymers within the film matrix and/or as part of the drug-containing deposit (e.g. one or more droplets) on the surface of the polymer.
  • the polymer component consists of a single water- soluble polymer.
  • the polymer component consists of two or more water-soluble polymers, including two or more of the same water-soluble polymers having different molecular weights.
  • the polymer component in the film matrix is of a suitable composition and present in a sufficient amount to ensure rapid disintegration of the film matrix in the oral mucosa.
  • the presence of the polymer component may allow the film matrix to disintegrate completely oromucosally in about 15 seconds to about 180 seconds, for example, about 30 seconds to about 180 seconds, including about 120 seconds.
  • the polymer component in the film matrix also provides the film with sufficient strength (i.e. the film is self-supporting).
  • the polymer component may, for example, consist of the water-soluble polymer hydroxypropyl cellulose, although different water-soluble polymers are also contemplated as described hereinafter under the definition “first water-soluble polymer” and “second water soluble polymer”.
  • the polymer component may consist of one, two or three hydroxypropyl celluloses having different molecular weights. The molecular weights of the different hydroxypropyl celluloses may conveniently range from (i) less than about 60,000 daltons (e.g.
  • the two or more hydroxypropyl celluloses may be mixed in any suitable ratio to achieve the desired droplet viscosity.
  • the viscosity of the dexmedetomidine composition solution or suspension can be measured using a Brookfield viscometer with a small sample adapter at a temperature of 25°C and may range from about 5 cps to about 3700 cps.
  • the viscosity of the dexmedetomidine composition solution or suspension is from about 6 cps to about 20 cps at 25°C and a shear rate of about 7 (1/s).
  • the polymer component may, for example, consist of one water soluble polymer or two different water-soluble polymers.
  • one of the water-soluble polymers may include the same polymer but present in the polymer component as a combination of different molecular weights.
  • the polymer component may consist of one, two or three hydroxypropyl celluloses having different molecular weights, although different water- soluble polymers are also contemplated as described hereinafter under the definition “first water- soluble polymer” and “second water soluble polymer” such as polyethylene oxide.
  • the molecular weights of the different hydroxypropyl celluloses may conveniently range from (i) less than about 60,000 daltons (e.g. about 5000 daltons to about 49000 daltons) (ii) about 90000 daltons to about 200,000 daltons and (iii) about 200,000 daltons to about 500,000 daltons (e.g. about 300000 daltons to about 450000 daltons).
  • the two or more hydroxypropyl celluloses e.g. low and high molecular weight hydroxypropyl celluloses
  • the polymer component may conveniently consist of one or more water-soluble polymers having a molecular weight less than about 60,000 daltons (e.g. about 5,000 daltons to about 49,000 daltons), and/or from about 90000 daltons to about 200,000 daltons and/or about 200,000 daltons to about 500,000 daltons (e.g. about 300000 daltons to about 450000 daltons).
  • a structurally different water-soluble polymer is also present, it may conveniently have a higher molecular weight, for example a molecular weight greater than about 500,000 daltons.
  • the disclosure provides pharmaceutical film compositions, comprising: (i) dexmedetomidine or a pharmaceutically acceptable salt thereof; (ii) a polymer component consisting of a first water-soluble polymer having a molecular weight less than about 60,000 daltons (e.g. about 5,000 daltons to about 49,000 daltons), and one or more second-water soluble polymers having a molecular weight greater than about 60,000 daltons; and, optionally, (iii) one or more pharmaceutically acceptable carriers.
  • the disclosure provides pharmaceutical film compositions consisting essentially of: (i) dexmedetomidine or a pharmaceutically acceptable salt thereof; (ii) a polymer component consisting of a first water-soluble polymer having a molecular weight less than about 60,000 daltons (e.g. about 5,000 daltons to about 49,000 daltons), and one or more second-water soluble polymers having a molecular weight greater than about 60,000 daltons; and, optionally, (iii) one or more pharmaceutically acceptable carriers.
  • the disclosure provides pharmaceutical film compositions consisting of (i) dexmedetomidine or a pharmaceutically acceptable salt thereof; (ii) a polymer component consisting of a first water-soluble polymer having a molecular weight less than about 60,000 daltons (e.g. about 5,000 daltons to about 49,000 daltons), and one or more second water-soluble polymers having a molecular weight greater than about 60,000 daltons; and, optionally, (iii) one or more pharmaceutically acceptable carriers.
  • Examples of one or more first water-soluble polymers are selected from the group consisting of hydroxypropyl cellulose (UPC), hydroxyethyl cellulose, hydroxypropyl methylcellulose (HPMC), carboxymethyl cellulose, methyl cellulose and mixtures thereof, including mixtures of the same polymer having different molecular weights.
  • UPC hydroxypropyl cellulose
  • HPMC hydroxypropyl methylcellulose
  • carboxymethyl cellulose methyl cellulose and mixtures thereof, including mixtures of the same polymer having different molecular weights.
  • Examples of one or more second water-soluble polymers are selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose and mixtures thereof, including mixtures of the same polymer having different molecular weights.
  • Polyethylene oxide (PEO) may also be present herein as a second water-soluble polymer or may be described separately hereinafter in the pharmaceutical film compositions as an example of a pharmaceutically acceptable carrier, or more particularly, as a mucoadhesive agent.
  • the weight ratio of said first water-soluble polymer to said second water- soluble polymer(s) (including PEO when present in the film) in the entire film composition is from about 2: 1 to about 1 :50, for example about 1 : 1 to about 1 :40, including about 1 : 1, about 1 :2, about 1 :3, about 1 :4, about 1 :5, about 1 :6, about 1 :7, about 1 :8, about 1 :9, about 1 : 10, about 1 : 11, about 1 : 12, about 1 : 13, about 1 : 14, about 1 : 15, about 1: 16, about 1 : 17, about 1 : 18, about 1 : 19, about 1 :20, about 1 :21, about 1 :22, about 1 :23, about 1:24, about 1 :25, about 1 :26, about 1 :27, about 1 :28, about 1 :29, about 1 :30, about 1 :31, about 1:32, about 1 :33, about 1 :34
  • the weight ratio of said first water-soluble polymer to said second water- soluble polymer(s) (including PEO when present in the film) in the entire film composition is from about 1 : 10 to about 1 :30, about 1 : 15 to about 1 :25 or about 1 : 15 to about 1 :20. In embodiments, a ratio of about 1 : 15 to about 1 :20 provides beneficial functional effects.
  • Examples of other water-soluble polymers which may be included in the film with the first water-soluble polymer/second water-soluble polymer or replace such polymer(s) include povidone (polyvinylpyrrolidone), copovidone (copolymers of N-vinyl-2-pyrrolidone and vinyl acetate), polyvinyl alcohol, polyethylene glycol, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl copolymers, polydextrose, pullulan, carboxymethyl cellulose, sodium alginate, chitosan, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum, starch, carrageenan, gelatin and mixtures thereof.
  • povidone polyvinylpyrrolidone
  • copovidone copolymers of N-vinyl-2-pyrrolidone and vinyl acetate
  • polyvinyl alcohol polyethylene glycol
  • polyacrylic acid methylmethacrylate cop
  • the water-soluble polymer component including water-soluble polymer carriers when present, may conveniently comprise about 40% to about 99.8%, about 50% to about 99.7%, about 60% to about 99.6% of the film composition, based on the weight of the film on a dry weight basis.
  • the polymer component for the film composition comprises a first water- soluble polymer present in an amount of from about 2% to about 15% on a dry weight basis of the polymer component (e.g. at about 3% to about 8% w/w of the total film weight).
  • This water- soluble polymer may conveniently have a molecular weight from about 5,000 daltons to about 49,000 daltons.
  • suitable such water-soluble polymers include those selected from the group consisting of hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, methyl cellulose, and mixtures thereof.
  • low molecular weight hydroxypropyl cellulose may be present in the film at about 3% to about 8% w/w of the total film weight.
  • the one or more second water-soluble polymers may, for example, be present in an amount of from about 50 to about 98 weight percent on dry weight basis of the polymer component.
  • the one or more second water-soluble polymers each has a molecular weight greater than 60,000 daltons; for example, from about 90,000 daltons to about 1,500,000 daltons, especially when the polymer is selected from the group consisting of polyethylene oxide, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, and mixtures thereof.
  • the one or more second water-soluble polymers may together be present in the film at about 25% to about 40% w/w of the total film weight when the one or more second water-soluble polymers each has a molecular weight from about 90,000 daltons to about 200,000 daltons and/or from about 200,000 daltons to about 500,000 daltons, and the polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, and mixtures thereof.
  • polyethylene oxide may be present in the film at about 50% to about 60% w/w of the total film weight.
  • the polymer component for the film composition consists of a low molecular weight, water-soluble polymer (e.g., having a molecular weight less than about 60,000 daltons) and one or more high molecular weight polymers (e.g., having a molecular weight greater about 60,000, up to about 1,500,000 daltons when a polyethylene oxide is included in the polymer mixture or up to about 500,000 daltons when a polyethylene oxide is not included in the polymer mixture).
  • This polymer combination especially when the polymers are a combination of hydroxypropyl cellulose and polyethylene oxide, lends certain advantages to the tensile strength and pharmacokinetics of the film composition.
  • the present disclosure provides a film composition comprising (e.g. consisting essentially of):
  • the present disclosure provides a film composition comprising (e.g. consisting essentially of):
  • a polymer component consisting of: (a) one or more first water-soluble polymer (e.g. hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, and mixtures thereof ) having a molecular weight from about 5,000 daltons to about 49,000 daltons, for example, in about 2 to about 15 weight percent on dry weight basis of the total polymer component; and (b) one or more second water-soluble polymers (e.g.
  • polyethylene oxide hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, and mixtures thereof
  • 60,000 daltons such as greater than 100,000 daltons, for example in about 50 to about 98 weight percent on dry weight basis of the total polymer component
  • the molecular weight of hydroxypropyl cellulose when present in the film of the present disclosure, may be varied, and may be present as both a low molecular weight, water-soluble polymer and as one or more high molecular weight, water-soluble polymers. In embodiments, the molecular weight may be less than about 60,000 daltons (e.g. about 5,000 daltons to about 49,000 daltons). In embodiments the molecular weight may be in the range from about 90,000 daltons to about 200,000 daltons. In embodiments, the molecular weight may be in the range from about 200,000 daltons to about 500,000 daltons.
  • Hydroxypropyl cellulose when part of the film composition including polyethylene oxide, may conveniently be present in the range from about 10% to about 90% by weight on a dry weight basis of the polymer component, e.g. about 20% to about 80% by weight on dry weight basis of the polymer component, e.g. about 20% to about 50% by weight on dry weight basis of the polymer component, e.g. about 25% to about 45% by weight on dry weight basis of the polymer component.
  • the molecular weight of polyethylene oxide when present in the film of the present disclosure, may also be varied.
  • a water-soluble, high molecular weight polyethylene oxide may be used, for example, to increase muco-adhesivity of the film.
  • the molecular weight may range from about 100,000 daltons to about 1,500,000 daltons, including about 100,000, 200,000, 300,000, 600,000, 900,000 or 1,000,000 daltons.
  • polyethylene oxide having a molecular weight of about 600,000 daltons to about 900,000 daltons with polyethylene oxide having a molecular weight of about 100,000 daltons to about 300,000 daltons in the polymer component.
  • Polyethylene oxide, when part of the film composition may conveniently be present in range from about 30% to about 90% by weight on a dry weight basis of the total polymer component, e.g. about 40% to about 85% by weight on a dry weight basis of the polymer component, e.g. about 55% to about 80% by weight on a dry weight basis of the polymer component.
  • Such film compositions may contain the drug dispersed within the film, or microdeposited onto a surface of the film.
  • the drug When micro-deposited on the surface of a “placebo” film, the drug may conveniently be added as part of a dexmedetomidine composition as one or more droplets in a liquid carrier, such as a solvent (e.g. an alcohol such as ethanol), optionally together with one or more (e.g. two) water-soluble polymers and/or pharmaceutically acceptable carriers.
  • Suitable water-soluble polymers include (1) a low molecular weight, water-soluble polymer, for example a low molecular weight, water-soluble polymer having a molecular weight of less than about 60,000 daltons (e.g.
  • Each water-soluble polymer may independently be selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, polyethylene oxide and methyl cellulose, e.g. hydroxypropyl cellulose and/or polyethylene oxide.
  • the dexmedetomidine composition comprises dexmedetomidine hydrochloride, a low molecular weight polymer which is hydroxypropyl cellulose and one or two high molecular weight polymers each of which are hydroxypropyl cellulose in an ethanol solvent.
  • the dexmedetomidine composition comprises dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. dexmedetomidine hydrochloride), hydroxypropyl cellulose (40,000MW) and one or both of hydroxypropyl cellulose (140,000MW) and hydroxypropyl cellulose (370,000MW).
  • the dexmedetomidine composition comprises dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. dexmedetomidine hydrochloride), and only two hydroxypropyl celluloses, namely hydroxypropyl cellulose (40,000MW) and hydroxypropyl cellulose (140,000MW).
  • dexmedetomidine hydrochloride e.g. dexmedetomidine hydrochloride
  • the deposition composition may be in any form, including as a solution, emulsion, suspension or dispersion.
  • the dexmedetomidine composition may be added as one or more droplets in an ethanol-based solution, optionally containing a pH- neutralizing agent such as sodium hydroxide.
  • the film substrate surface contains two or more micro-deposited spots of dexmedetomidine hydrochloride (e.g. two micro-deposited spots) in a polymer matrix.
  • the viscosity of deposition solution/ suspension may range from about 6 cps to about 3700 cps as measured at 25°C using a Brookfield viscometer with a small sample adapter.
  • it may range from about 5 cps to about 500 cps, about 6 cps to about 200 cps, about 6 cps to about 100 cps or about 6 cps to about 50 cps.
  • the viscosity of the dexmedetomidine composition is from about 6 cps to about 20 cps at 25°C and a shear rate of about 7 (1/s).
  • the film Following drying to remove the solvent, the film comprises a film substrate (e.g. a placebo) with the dexmedetomidine composition as previously described but absent the solvent deposited (e.g. micro-deposited) on the surface of the film substrate.
  • the dried composition containing dexmedetomidine or a pharmaceutically acceptable salt thereof may cover the whole of the film substrate surface or only part of the film substrate surface.
  • the dried dexmedetomidine composition appears as one or more discrete drug-containing droplets on the film substrate surface.
  • stenciling may be used to achieve a one or more defined and discrete regions of drug-containing composition on the surface of the film substrate.
  • the disclosure provides a dry film product comprising a film substrate with one or more discrete drug-containing droplets on the film substrate surface, wherein each such drug-containing droplet comprises dexmedetomidine or a pharmaceutically acceptable salt thereof , and hydroxypropyl cellulose of two molecular weights: hydroxypropyl cellulose (40,000MW) available as HPC-SSL, and hydroxypropyl cellulose (140,000MW) marketed under the tradename of KlucelTM Type JF NF, and wherein the film substrate comprises hydroxypropyl cellulose of three molecular weights: hydroxypropyl cellulose (40,000MW), hydroxypropyl cellulose (140,000MW), and hydroxypropyl cellulose (370,000MW) marketed under the tradename of KlucelTM Type GF NF.
  • the film substrate also comprises polyethylene oxide (600,000MW) available under the name of Sentry Polyox WSR 205 LEO NF.
  • the dry film product comprises a deposition composition (also referred to herein as a “dexmedetomidine composition”) comprising: (i) dexmedetomidine hydrochloride, present at about 9% to about 50% w/w of the deposition composition, e.g.
  • the film also comprises a polymer matrix, wherein the polymer matrix comprises:
  • hydroxypropyl cellulose (40,000MW) present at about 3% to about 40% w/w of the polymer matrix; (ii) hydroxypropyl cellulose (140,000MW) present at about 3% to about 40% w/w of the polymer matrix; (iii) hydroxypropyl cellulose (370,000MW) present at about 0% to about 30% w/w of the polymer matrix, and (iv) polyethylene oxide (600,000MW) present at about 55% to about 75% w/w of the polymer matrix.
  • the dry film product (e.g. a micro-deposited film product) comprises(i) dexmedetomidine hydrochloride, present at about 1% to about 50% w/w of the total film weight;
  • hydroxypropyl cellulose (40,000MW), present at about 2% to about 30% w/w of the total film weight ;
  • hydroxypropyl cellulose (140,000MW) present at about 2% to about 30% w/w of the total film weight ;
  • hydroxypropyl cellulose (370,000MW) present at about 10% to about 50% w/w of the total film weight
  • polyethylene oxide 600,000MW
  • the films disclosed herein combine several types of hydroxypropyl cellulose (HPC) to provide a film with advantageous properties.
  • the film composition may contain two or three of hydroxypropyl cellulose (40,000MW), hydroxypropyl cellulose (140,000MW) and hydroxypropyl cellulose (370,000MW) in combination.
  • polyethylene oxide (600,000MW) is included with these types of HPC when part of a monolithic film.
  • a low molecular weight hydroxypropyl cellulose (e.g. 40,000MW) is present at about 3% to about 8% (e.g. about 5%) w/w of the total film weight
  • a high molecular weight hydroxypropyl cellulose (e.g. 140,000MW) is present at about 3% to about 8% (e.g. about 5%) w/w of the total film weight
  • a high molecular weight hydroxypropyl cellulose e.g. 370,000MW
  • polyethylene oxide e.g. 600,000MW
  • the two high molecular weight, water-soluble polymers are together present at about 25% to about 40% w/w of the total film weight.
  • the selection and ratio of water-soluble polymers can be made to effect complete dissolution of the film composition in oral mucosal fluids within seconds to minutes, e.g. in about 0.25 minutes to about 15 minutes, thus ensuring delivery of a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof via the oral mucosa.
  • the film compositions may reside in the sublingual or buccal region of the mouth up to about 15 minutes, up to about 10 minutes, or up to about 5 minutes, including for a period of from about 30 seconds to about 15 minutes, about 1 minute to about 10 minutes, or about 1 minute to about 5 minutes.
  • dissolution medium will essentially depend as per the sink conditions and highest dose of drug.
  • the temperature of dissolution medium should be maintained at 37 ⁇ 0.5°C and rpm at 50 (see Bala et al., in Int J Pharm Investigation, vol. 3(2), pages 67-76).
  • thin films compositions of the disclosure have several functional advantages to promote rapid onset of drug effect.
  • thin films compositions of the disclosure have a disintegration time (DT) of about 15 seconds to about 180 seconds, about 15 seconds to about 160 seconds, about 25 seconds to about 150 seconds, about 15 seconds to about 140 seconds, about 15 seconds to about 120 seconds, about 40 seconds to about 120 seconds, about 50 seconds to about 120 seconds, for example about 120 seconds, when applied oromucosally (e.g. sublingually or buccally).
  • DT disintegration time
  • a disintegration time in this time-frame provides optimal onset of drug effects.
  • thin film compositions of the disclosure have mucoadhesion properties that provide practical benefits of localizing the film to the sublingual location and reducing, or preventing, effective removal prior to dissolution. This quality is particularly advantageous in a clinical setting with an agitated subject.
  • thin film compositions have a mucoadhesion force (the mucoadhesion strength or shear strength) of about 50g or above, about 100g or above, about 200g or above, about 300g or above, about 400g or above, about 500g or above, about 600g or above, about 700g or above, about 800g or above, about 900g or above, about 1000g or above.
  • the mucoadhesion force is in a range of about 300g to about 4000g, about 500g to about 3000g, or about 1000g to about 2000g.
  • Burst strength of the film also contributes to drug delivery.
  • Certain thin film compositions of the disclosure have a burst strength at or above 50g, 100g, 200g, 300g, 400g, 500g, 600g, 700g, 800g, 900g, 1000g, 1100g, 1200g, 1300g, 1400g, 1500g, 1600g, 1700g, 1800g, 1900g, 2,000 g, 2,500g, 3,000g, 3,500g, 4,000g, 4,500g, 5,000g, 5,500g, 6,000g, 6,500g, 7,000g, 7,500g, 8,000g, 8,500g, 9,000g, 9,500g, 10,000g or 15,000g.
  • the burst strength may be in a range of about 200g to about 15000 g, about 300 g to about 10,000 g, or about 400 g to about 5,000 g.
  • the film compositions may further comprise one or more pharmaceutically acceptable carriers that includes, but is not limited to, liquid carriers, flavours, sweeteners, refreshing agents, antioxidants, pH adjusting agents, permeation enhancers, mucoadhesive agents, plasticizers, bulking agents, surfactants/non-ionic solubilizers, stabilizers, anti-foam agents, colors or the like.
  • the film compositions are substantially free of acidic buffer or other acidic agents.
  • the pharmaceutically acceptable carrier includes a liquid carrier.
  • the liquid carrier comprises one or more solvents useful in the preparation of the polymer matrix (drug containing or placebo) and deposition composition on the polymer matrix.
  • the solvent may be water.
  • the solvent may a polar organic solvent including, but are not limited to, ethanol, isopropanol, acetone, butanol, benzyl alcohol and mixtures thereof.
  • the solvent may be a non-polar organic solvent, such as methylene chloride, toluene, ethyl acetate and mixtures thereof. Certain solvents are alcohols, especially ethanol, water and mixtures thereof.
  • the solvent content in the wet polymer matrix is at least about 30% by weight of the total wet weight of the total film composition prior to drying.
  • the subsequent dried film composition will desirably contain less than about 10% by weight of solvent, more desirably less than about 8% by weight of solvent, even more desirably less than about 6% by weight of solvent and most desirably less than about 2% by weight of solvent.
  • Flavors may be chosen from natural and synthetic flavoring liquids.
  • An illustrative list of such agents includes volatile oils, synthetic flavor oils, flavoring aromatics, oils, liquids, oleoresins or extracts derived from plants, leaves, flowers, fruits, stems and combinations thereof.
  • Non-limiting flavor oils include: spearmint oil, cinnamon oil, peppermint oil, clove oil, bay oil, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, and oil of bitter almonds.
  • the flavor is a peppermint oil flavour available as peppermint oil, NF.
  • the amount may be varied in order to obtain the result desired in the final product. Such variations are within the capabilities of those skilled in the art without the need for undue experimentation. In general, amounts of about 0.1 % to about 30 wt % may be used in the films to supply flavoring. Suitable sweeteners include both natural and artificial sweeteners.
  • suitable sweeteners include, e.g.: water-soluble sweetening agents such as monosaccharides, disaccharides and polysaccharides such as xylose, ribose, glucose (dextrose), mannose, galactose, fructose (levulose), sucrose (sugar), high fructose corn syrup, maltose, invert sugar (a mixture of fructose and glucose derived from sucrose), partially hydrolyzed starch, corn syrup solids, and dihydrochalcones; water-soluble artificial sweeteners such as the soluble saccharin salts, i.e., sodium or calcium saccharin salts, cyclamate salts and water-soluble sweeteners derived from naturally occurring water-soluble sweeteners, such as a chlorinated derivatives of ordinary sugar (sucrose), known, for example, as sucralose.
  • the sweetener is sucralose.
  • Flavoring agents, sweeteners and refreshing agents can be added in conventional quantities, generally up to a total amount of about 0.01% to about 10% of the weight of the film on a dry weight basis, e.g. from about 0.1% to about 7% of the weight of the film on a dry weight basis, e.g. about 0.1% to about 5% based on the weight of the film on a dry weight basis.
  • Other taste-masking agents include, for example polymers, oils, or waxes.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is coated with a taste-masking agent prior to formulation of the film compositions.
  • a tastemasking agent used to coat the active ingredient, it may be present in an amount of from about 5% to about 80% by weight of the particle or granule containing the active ingredient. In embodiment, the taste-masking agent is present in an amount from about 25% to about 35% by weight of the particle or granule containing the active ingredient.
  • oxygen scavengers or antioxidants that substantially improve long-term stability of the film composition against oxidative degradation include sulfite salts, such as sodium sulfite, sodium bisulfite, sodium metabisulfite and analogous salts of potassium and calcium.
  • sulfite salts such as sodium sulfite, sodium bisulfite, sodium metabisulfite and analogous salts of potassium and calcium.
  • a suitable amount of the sulfite salt e.g., sodium sulfite
  • the absorption of dexmedetomidine or a pharmaceutical acceptable salt thereof through the oral mucosa may increase in an alkaline microenvironment. As an example, this may be achieved when the film compositions are maintained at a pH of above 6, from about 6 to about 9, or about 6.5 to about 8.
  • the film may include an alkaline substance that increases the pH of the film product.
  • pH-adjusting/pH-neutralizing agents include bicarbonates (e.g., sodium bicarbonate), citrates (e.g., potassium citrate), carbonates (e.g., calcium carbonate), lactates (e.g., sodium lactate), acetates (e.g., calcium acetate), alkaline buffer (e.g.
  • glycine glycine
  • sodium hydroxide sodium chloride or the like.
  • An alkaline buffer such as glycine, is one example of a pH-neutralizing agent.
  • a suitable amount of pH-adjusting/pH-neutralizing agent present in the film composition includes, for example, up to about 10%, e.g. about 1% to about 5% based on the weight of the film composition on a dry weight basis
  • Certain effective penetration enhancers that promote absorption of dexmedetomidine or a pharmaceutically acceptable salt thereof across the oral mucosa include alcohols.
  • An alcohol penetration enhancer, such as butanol, can conveniently be added to the film composition in an amount of up to about 10%, e.g. about 0.1% to about 5%, e.g. about 1% to about 3% based on the weight of the film composition on a dry weight basis.
  • Mucoadhesive agents such as butanol
  • One mucoadhesive agent is polyethylene oxide, which may conveniently be added to the film composition in an amount of from about 20% to about 90%, e.g. about 40% to about 70% based on the total weight of the film composition on a dry weight basis.
  • Plasticizers that can be effectively employed herein include polyethylene glycol, propylene glycol, tributyl citrate, tri ethyl citrate and glycerol.
  • a suitable amount of plasticizer included in the film composition may typically be up to about 10%, e.g. about 0.1% to about 5%, e.g. about 0.5% to about 5% based on the weight of the film on a dry weight basis.
  • higher molecular weight polyethylene glycols may be utilized, including polyethylene oxide.
  • Suitable fillers that can be added to a film composition include starch, calcium salts, such as calcium carbonate, and sugars, such as lactose, glucose, sucrose, mannose, sorbitol, mannitol, galactitol, sucralose, trehalose and combinations thereof.
  • the amount of filler that can conveniently be added to the film formulation is typically up to about 25%, e.g. about 0.5% to about 20%, e.g. about 1% to about 15%, e.g. about 2% to about 10%, based on the weight of the film composition on a dry weight basis.
  • the film typically incorporates at least one surfactant/non-ionic solubilizer including, for example, but are not limited to, a poloxamer, polyoxyl hydrogenated castor oil, glyceryl polyethylene glycol oxystearates, fatty acid glyceryl polyglyceryl esters, polyglyceryl esters, and combinations thereof.
  • the amount of surfactant(s) that can be added to the film composition is typically up to about 5%, e.g. about 0.5% to about 3%, e.g. about 1% to about 3% based on the weight of the film composition on a dry weight basis.
  • Simethicone is an example of a useful anti-foaming and/or de-foaming agent, although other anti-foaming and/or de-foaming agents may suitable be used.
  • An anti-foaming and/or defoaming agent such as simethicone may be added to the film composition in an amount from about 0.01 % to about 5.0%, more desirably from about 0.05% to about 2.5%, and most desirably from about 0.1% to about 1.0% based on the weight of the film composition on a dry weight basis.
  • Colorants such as simethicone may be added to the film composition in an amount from about 0.01 % to about 5.0%, more desirably from about 0.05% to about 2.5%, and most desirably from about 0.1% to about 1.0% based on the weight of the film composition on a dry weight basis.
  • Color additives that may be included in a film composition include food, drug and cosmetic colors (FD&C), drug and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C). These colors are dyes, their corresponding lakes, and certain natural and derived colorants. Certain examples of color additives are inorganic pigments, such as oxides of iron or titanium, added in concentrations ranging from about 0.001% to about 10%, e.g. about 0.01% to about 3%, based on the weight of the film composition on a dry weight basis. In embodiments, the color used for the dexmedetomidine composition (i.e. the deposit composition) is different from the color used for the film substrate (e.g. the placebo film).
  • One color of the monolithic film and the film substrate of the micro-deposited film is emerald green, and available as Fast Emerald Green Shade (06507).
  • One color of the dexmedetomidine composition i.e. the deposit composition
  • a film comprising about 180 pg of dexmedetomidine or a pharmaceutically acceptable salt thereof containing two blue color microdeposited spots of dexmedetomidine hydrochloride on the green color film substrate .
  • a film comprising about 120 pg of dexmedetomidine or a pharmaceutically acceptable salt thereof.
  • a self-supporting, dissolvable, film comprising:
  • a self-supporting, dissolvable, film comprising: (i) about 120 ⁇ g of dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. the hydrochloride salt);
  • the just-mentioned one or more water-soluble polymers (ii) of embodiment (A) or (B) above comprises a low molecular weight, water-soluble polymer and two high molecular weight, water-soluble polymers, for example wherein the low molecular weight, water-soluble polymer has a molecular weight from about 5,000 daltons to about 49,000 daltons (e.g. about 40,000 daltons), and each high molecular weight, water-soluble polymer has a molecular weight of greater than about 60,000 daltons (e.g.
  • each water-soluble polymer is, in some embodiments, hydroxypropyl cellulose.
  • the polyethylene oxide in some embodiments, has a molecular weight of about 600,000 daltons.
  • a pharmaceutical film composition comprising or consisting essentially of therapeutically effective amount of dexmedetomidine or pharmaceutically acceptable salt thereof and one or more excipients selected from polyethylene oxide, hydroxypropyl cellulose, sucralose, peppermint oil, emerald green colorant, and FD&C blue colorant.
  • a self-supporting, dissolvable, film comprising:
  • the film components excluding dexmedetomidine or a pharmaceutically acceptable salt thereof form a single layer film substrate, and dexmedetomidine or a pharmaceutically acceptable salt thereof is present on the surface of the film substrate (e.g. within a composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof, a low molecular weight, water- soluble polymer having a molecular weight of about 40,000 daltons, and a high molecular weight, water-soluble polymer having a molecular weight of about 140,000 daltons).
  • Each water-soluble polymer is, in some embodiments, hydroxypropyl cellulose.
  • a self-supporting, dissolvable, film comprising:
  • composition consisting essentially of:
  • polyethylene oxide 600,000MW
  • composition of part (a) is present on the surface of the film substrate (b).
  • a self-supporting, dissolvable, film comprising: (a) a composition consisting essentially of:
  • polyethylene oxide 600,000MW
  • composition of part (a) is present on the surface of the film substrate (b).
  • dexmedetomidine hydrochloride is present at about 0.1% to about 2% w/w of the total film weight
  • hydroxypropyl cellulose (40,000MW) is present at about 4% to about 8 % w/w of the total film weight
  • hydroxypropyl cellulose (140,000MW) is present at about 4% to about 8 % w/w of the total film weight
  • hydroxypropyl cellulose (370,000MW) is present at about 25 % to about 30% w/w of the total film weight
  • polyethylene oxide (600,000MW) is present at about 50% to about 60% w/w of the total film weight.
  • the present disclosure provides pharmaceutical buccal film compositions comprising or consisting essentially of therapeutically effective amount of dexmedetomidine or pharmaceutically acceptable salt thereof, one or more mucoadhesive polymers and optional excipients selected from one or more of plasticizers, penetration enhancers, coloring agents, sweetening agents, flavoring agents, taste-making agents or salivary stimulants.
  • Mucoadhesive polymers may be selected from hydrophilic polymers and hydrogels.
  • hydrophilic polymers examples include polyvinyl alcohol [PVA], sodium carboxy methylcellulose [NaCMC], hydroxyl propyl methyl cellulose [HPMC], hydroxyl ethyl cellulose and hydroxypropyl cellulose [UPC],
  • hydrogels include anionic polymers like carbopol, polyacrylates, cationic polymers like chitosan and non-ionic polymers like Eudragit analogues.
  • the present disclosure provides pharmaceutical spray compositions or drop compositions suitable for oromucosal (e.g. sublingual or buccal) administration comprising or consisting essentially of a therapeutically effective amount of dexmedetomidine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable liquids (from about 1% to about 99.995% by weight).
  • Such liquids may be solvents, co-solvents, or nonsolvents for dexmedetomidine or a pharmaceutically acceptable salt thereof.
  • Examples of pharmaceutically acceptable liquids include water, ethanol, dimethyl sulfoxide, propylene glycol, polyethylene glycol, propylene carbonate, glycerine, N-methylpyrrolidone, pharmaceutically acceptable oils (e.g., soybean, sunflower, peanut, etc.) or the like.
  • the pharmaceutically acceptable liquid is selected either to dissolve dexmedetomidine or pharmaceutically acceptable salt thereof, to produce a stable, homogenous suspension of it, or to form any combination of a suspension or solution.
  • spray or drop formulations of dexmedetomidine or pharmaceutically acceptable salt thereof may include one or more excipients such as viscosity modulating materials (e.g.
  • polymers such as polyvinylpyrrolidone (PVP)); preservatives (e.g., ethanol, benzyl alcohol, propylparaben and methylparaben); flavoring agents (e.g. peppermint oil), sweeteners (e.g., sugars such as sucrose, glucose, dextrose, maltose, fructose, etc.), artificial sweeteners (e.g. saccharin, aspartame, acesulfame, sucralose), or sugar alcohols (e.g.
  • PVP polyvinylpyrrolidone
  • preservatives e.g., ethanol, benzyl alcohol, propylparaben and methylparaben
  • flavoring agents e.g. peppermint oil
  • sweeteners e.g., sugars such as sucrose, glucose, dextrose, maltose, fructose, etc.
  • artificial sweeteners e.g. saccharin, aspartame
  • oromucosal gel formulations of dexmedetomidine or pharmaceutically acceptable salt thereof may include one or more excipients such as viscosity modulating materials (e.g. water soluble or water swellable polymers such as carbopol, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose).
  • viscosity modulating materials e.g. water soluble or water swellable polymers such as carbopol, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose).
  • Sprays, drops, and gels may be made by mixing appropriate quantities of the foregoing ingredients in accordance with standard good manufacturing practices. Such excipients may be included in the formulation to improve patient or subject acceptance or taste, to improve bioavailability, to increase shelf-life, to reduce manufacturing and packaging costs, to comply with requirements of governmental regulatory agencies, and for other purposes. The relative amounts of each ingredient should not interfere with the desirable pharmacological and pharmacokinetic properties of the resulting formulation. [0165] In embodiments, there is provided an oromucosal spray composition comprising or consisting essentially of therapeutically effective amount of dexmedetomidine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carrier or excipients.
  • a patient may, in one embodiment, be treated by administering sublingually or buccally 1 to 2 actuations from a spray pump.
  • An advantage of spray delivery is the ability to easily titrate patients by 1 or 2 doses as required by a single actuation.
  • Pump action sprays are characterized in requiring the application of external pressure for actuation, for example, external manual, mechanical or electrically initiated pressure. This is in contrast to pressurized systems, e.g., propellant-driven aerosol sprays, where actuation is typically achieved by controlled release of pressure e.g., by controlled opening of a valve.
  • compositions comprising dexmedetomidine hydrochloride at doses of 20 pg, 30 pg, 60 pg, 90 pg, 120 pg and 180 pg and excipients as described in table 2.
  • the present disclosure provides tablet formulations suitable for oromucosal administration (e,g. sublingual or buccal administration) comprising or consisting essentially of therapeutically effective amount of dexmedetomidine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carrier (from about 1% to about 99.995% by weight).
  • Such carriers may be taste masking agents, diluents, disintegrants, binders, lubricants, glidants, flavouring agents or liquid solvents.
  • Examples of pharmaceutically acceptable liquids include water, ethanol, dimethyl sulfoxide, propylene glycol, polyethylene glycol, propylene carbonate, glycerine, N-methylpyrrolidone, pharmaceutically acceptable oils (e.g., soybean, sunflower, peanut, etc.) or the like.
  • Taste masking agents include, for example, amberlite, Opadry® AMB TAN, polymethacrylates (especially Eudragit® L100), sodium starch glycolate (Primojel), carbopol polymers, PEG-5M, sodium acetate, ethylcellulose, betacyclodextrin.
  • Flavouring agents may be, for example, mint powder, menthol, vanillin, aspartame, acesulfame potassium, saccharin.
  • Disintegrants include, for example, sodium starch glycolate, low- substituted hydroxy propyl cellulose, alginic acid, carbon dioxide, carboxymethylcellulose calcium, carboxymethylcellulose sodium, croscarmellose sodium, guar gum, methylcellulose, polacrilin potassium, poloxamer, sodium alginate.
  • Diluents may be, for example, microcrystalline cellulose, dextrates, dextrose, fructose, mannitol, sucralose, sorbitol, starch, pregelatinized starch, sucrose, xylitol, maltose, maltodextrin, maltitol.
  • Binders may be, for example, alginic acid, carbomer, ethyl cellulose, gelatine, liquid glucose, guar gum, hydroxyethyl cellulose, methylcellulose, polydextrose, polyethylene oxide, hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium alginate.
  • At least one lubricant may conveniently be incorporated into the formulation to prevent the powder from adhering to tablet punches during the compression procedure.
  • Lubricants may be, for example, talc, magnesium stearate, calcium stearate, glyceryl behenate, hydrogenated castor oil, stearic acid, sodium lauryl sulphate.
  • Glidants are used to promote powder flow by reducing interparticle friction and cohesion. These are used in combination with lubricants as they have no ability to reduce die wall friction.
  • Glidants may be, for example, colloidal silicon dioxide, calcium silicate, calcium phosphate tribasic.
  • Table 4 Buccal tablet formulation embodiments according to the disclosure.
  • Table 5 Sublingual tablet formulation embodiments according to the disclosure.
  • Liquid pharmaceutical compositions for parenteral administration may be formulated for administration by injection or continuous infusion. Routes of administration by injection or infusion can include, but are not limited to, intravenous, intraperitoneal, intramuscular, intrathecal, and subcutaneous.
  • parenteral formulations can include prefilled syringes, vials, powder for infusion for reconstitution, concentrate for infusion to be diluted before delivery (ready to dilute) or solutions (ready to use).
  • Injectable pharmaceutical compositions can be aqueous isotonic solutions or suspensions, and suppositories can be prepared from fatty emulsions or suspensions.
  • compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
  • Injectable formulation may further contain liquid vehicles (oily or aqueous), suspending agent, stabilizing and/or dispersing agents, solubilizing agents or solubilizers or surfactants, preservative, pH adjusters, tonicity adjusters or the like.
  • dry powder form injection or sterile solid lyophilized powder(s) of the active ingredient(s) with suitable vehicle, such as sterile, pyrogen-free water may also be used for injection compositions.
  • suitable vehicle such as sterile, pyrogen-free water
  • the parenteral compositions may be supplied in various delivery forms, e.g. ampoules, pre-filled syringes, needle or needle free auto-injectors, as a small volume infusion or in multidose containers with an added preservative.
  • the pharmaceutical compositions of the present disclosure include biodegradable subcutaneous implant, osmotically controlled device, subcutaneous implant, subcutaneous sustained release injection, lipid nanoparticles, liposomes, and the like.
  • Liquid preparations can include, but are not limited to, solutions, suspensions and emulsions. Such preparations are exemplified by water or water/propylene glycol solutions for parenteral injection. Liquid preparations may also include solutions for intranasal administration.
  • the liquid vehicle used for the preparation of the intramuscular injection may be, for example, water, a saline solution, another aqueous liquid (aqueous solvent) or non-aqueous liquid (non-aqueous solvent).
  • the parenteral formulations of the present disclosure can be sterilized.
  • sterilization techniques include filtration through a bacterial-retaining filter, terminal sterilization, incorporation of sterilizing agents, irradiation, and heating.
  • Administration of the above-described parenteral formulations may be by periodic injections of a bolus of the preparation, or may be administered by intravenous or intraperitoneal administration from a reservoir which is external (e.g., an intravenous bag) or internal (e.g., a bioerodable implant, a bioartificial or organ). See, e.g., U.S. Patent Nos. 4,407,957 and 5,798,113, each incorporated herein by reference in their entireties. Intrapulmonary delivery methods and apparatus are described, for example, in U.S. Patent Nos. 5,654,007, 5,780,014, and 5,814,607, each incorporated herein by reference in their entireties.
  • parenteral delivery systems include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, pump delivery, encapsulated cell delivery, liposomal delivery, needle-delivered injection, needleless injection, nebulizer, aerosolizer, electroporation, and transdermal patch.
  • Needle-less injector devices are described in U.S. Patent Nos. 5,879,327; 5,520,639; 5,846,233 and 5,704,911, the specifications of which are herein incorporated herein by reference in their entireties. Any of the formulations described herein can be administered in these methods. Further injectable formulations of dexmedetomidine are disclosed in U.S. Patent No. 8,242,158, U.S.
  • the intramuscular composition of the present disclosure comprises dexmedetomidine, or a pharmaceutically acceptable salt thereof, at a concentration of between about 0.05 pg/mL and about 15 pg/mL, sodium chloride at a concentration of between about 0.01 and about 2.0 weight percent and pH in the range of about 1 to about 10.
  • the intramuscular compositions of the present disclosure can be manufactured by the skilled person by use of standard methods and conventional techniques appropriate to the desired formulation.
  • the formulation for intramuscular administration of the present disclosure can be packed and/or stored in a suitable container, including, without limitation, syringes, ampoules, vials, including sealed vials such as vials the openings of which are sealed with syringe pierceable septa or sure-seals caps, and the like.
  • a suitable container including, without limitation, syringes, ampoules, vials, including sealed vials such as vials the openings of which are sealed with syringe pierceable septa or sure-seals caps, and the like.
  • the formulation is pre-filled in disposable syringes for self-administration by patients, with or without an auto-injector.
  • the present disclosure includes oral formulations that can be used for delivering dexmedetomidine.
  • oral formulations includes tablets, orally disintegrating tablets, mouth dissolving tablets, wafers, solution, suspension, emulsions, and capsules.
  • the disclosure encompasses oral disintegrating tablets comprising dexmedetomidine or a pharmaceutically acceptable salt thereof and at least one orally disintegrating carrier, wherein the oral disintegrating tablet disintegrates in about 0.5 to about 120 seconds and/or a therapeutically effective amount of the dexmedetomidine is absorbed into the bloodstream within about 1 to about
  • a therapeutically effective amount of the dexmedetomidine is absorbed into the bloodstream within about 3 minutes.
  • a method of treating mania associated with a diseased condition in a subject in need thereof comprising administering oromucosally (for example, sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the subject having a manic episode is in an agitated state.
  • the subject having a manic episode is in a non-agitated state.
  • the diseased condition is neuropsychiatric disorder such as bipolar disorder (such as bipolar I disorder and bipolar II disorder).
  • Bipolar disorders can be diagnosed by the clinical evaluation of patients using the criteria specified in the Diagnostic and Statistical Manual (DSM-IV) of the American Psychiatric Association. This disorder is distinct from the more common form of depression, called Major Depressive Disorder, in which patients only experience recurrent episodes of depression but no mania. Episodes of mania occur in patients who suffer from bipolar disorder which is an illness characterized by alternating cycles of depression and mania.
  • a method of treating bipolar mania in a subject in need thereof comprising administering oromucosally (for example, sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the present disclosure provides an oromucosal composition for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers wherein the mania is associated with a neuropsychiatric disease.
  • the present disclosure provides an oromucosal composition for treating mania in a subject in need thereof, wherein said mania is associated with bipolar disorder (bipolar I disorder and bipolar II disorder).
  • the present disclosure provides an oromucosal composition for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers wherein the mania is associated with bipolar disorder.
  • the mania is acute. In embodiments, the mania is recurring. In embodiments, the mania is a single episode.. In embodiments, the acute mania is associated with acute manic and/or mixed episodes. In embodiments, mania includes hypomania. In embodiments, the mania is mixed mania. In embodiments, the mania is dysphoric mania. In embodiments, the mania is mild. In embodiments, mania is severe. Signs of mania include anxiety with depression, restlessness, affective lability, prominent irritability and emotional reactivity.
  • a method of treating mania associated with neuropsychiatric disorders in a subject in need thereof comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis for at least one month wherein said subject is in a non-agitated state.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered for at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or at least one year.
  • mania is associated with depression.
  • the mania is associated with bipolar disorder.
  • a method of treating mania associated with neuropsychiatric disorders in a subject in need thereof comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis for at least one month wherein said subject is in an agitated state.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered for at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or at least one year.
  • mania is associated with depression.
  • the mania is associated with bipolar disorder.
  • a method of treating mania associated with neurodegenerative disorders comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis for at least one month.
  • dexmedetomidine or a pharmaceutically acceptable salt is administered for at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or at least one year.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg to about 405 pg, such as about 120 pg to about 270 pg, or at a dose of about 180 pg to about 405 pg, such as about 180 pg to about 270 pg, including administering doses of about 120 pg or about 180 pg, to treat mania in a human subject.
  • the present disclosure provides methods of treating mania in a human subject with diseased condition, without also inducing significant sedation, comprising administering one or more doses of dexmedetomidine or a pharmaceutically acceptable salt thereof in a day wherein the dose of dexmedetomidine or a pharmaceutically acceptable salt is about 30 pg to about 180 pg.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered oromucosally at a dose of about 2 pg to about 300 pg, such as about 10 pg to about 250 pg, or at a dose of about 10 pg to about 200 pg, such as about 30 pg to about 180 pg, including administering doses of about 30 pg, 60 pg, 90 pg, 120 pg or about 180 pg, to treat mania in a human subject, without also inducing significant sedation wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered on a daily basis for at least one month.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered once a day. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at night-time on a daily basis. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of 120 pg at night-time on a daily basis. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of 180 pg at night-time on a daily basis. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is also administered at day-time on an as needed basis.
  • the dosage of dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered twice a day.
  • the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered at a dose of about 30 pg to about 90 pg during daytime (e.g., 30 pg, 45 pg, 60 pg, or 90 pg) and about 120 pg to about 180 pg during night-time (e.g., 120 pg or 180 pg).
  • the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered at a dose of about 30 pg to about 90 pg during daytime and 30 pg to about 90 pg during night-time. In embodiments, the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered twice a day at a dose of about 120 pg to about 180 pg during daytime and about 30 pg to about 90 pg during nighttime.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered as 60 pg per unit dose twice a day to a total dose of 120 pg.
  • a 60 pg unit dose is taken in the morning and another 60 pg unit dose is taken in the evening or night-time.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered oromucosally at a daily dose of about 2 pg to about 300 pg, such as about 10 pg to about 250 pg, or at a dose of about 10 pg to about 200 pg, such as about 30 pg to about 180 pg, including administering doses of about 30 pg, 60 pg, 90 pg, 120 pg or about 180 pg, to treat mania in a human subject, without also inducing significant sedation wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered on a daily basis for at least one month.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered once a day. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at night-time once a day. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of 120 pg at night-time once a day. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of 180 pg at night-time once a day. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is also administered at day-time on as needed basis. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered on an as-needed basis at a different dose than the night-time dose.
  • the present disclosure provides a method of treating mania in a human subject with the diseased condition, without also inducing significant sedation, comprising administering dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. the hydrochloride salt) as a single dose of about 30 pg, about 60 pg, about 90 pg, about 120 pg or about 180 pg, each dose administered one to five times a day.
  • the treatment is effective without causing clinically significant cardiovascular effects.
  • the present disclosure provides a method of treating an acute manic episode associated with the diseased condition in a human subject, comprising oromucosally administering a film composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. hydrochloride salt) as a single dose of 30 pg, 60 pg, 90 pg, 120 pg or 180 pg.
  • an additional dose e.g. 30 pg, 60 pg or 90 pg,
  • a suitable period of time e.g. 2-hours
  • the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at night-time once a day.
  • the present disclosure provides a method of treating recurring mania associated with the diseased condition in a human subject, comprising oromucosally administering a film composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. hydrochloride salt) as a single dose of 30 pg, 60 pg, 90 pg, 120 pg or 180 pg.
  • an additional dose e.g. 30 pg, 60 pg or 90 pg
  • a suitable period of time e.g. 2-hours
  • the dexmedetomidine or a pharmaceutically acceptable salt thereof e.g.
  • hydrochloride salt is administered at night-time once a day.
  • the dexmedetomidine or a pharmaceutically acceptable salt thereof e.g. hydrochloride salt
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered sublingually in the form of a film.
  • the film is placed under the tongue, close to the base of the tongue, on the left or right side.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered buccally in the form of a film, patch or tablet, particularly a film.
  • the film is placed against the inner lip or cheek, close to the jaw line.
  • the present disclosure provides an oromucosal film composition for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, one or more water-soluble polymers and one or more pharmaceutically acceptable excipients and/or carriers.
  • the film is mucoadhesive.
  • the film has a disintegration time of about 10 seconds to about 60 seconds.
  • the present compositions are in the form of an oromucosal tablet for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the present compositions are in the form of an oromucosal spray formulation for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the present compositions are in the form of an oromucosal drop formulation for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • compositions are in the form of an oromucosal gel formulation for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered to the subject by oral route.
  • the present compositions are in the form of oral tablets, orally disintegrating tablets (ODTs), effervescent tablets, capsules, pellets, pills, lozenges or troches, powders, dispersible granules, catchets, aqueous solutions, syrups, emulsions, suspensions, solutions, soft gels, dispersions and the like.
  • ODTs orally disintegrating tablets
  • effervescent tablets effervescent tablets, capsules, pellets, pills, lozenges or troches
  • powders dispersible granules, catchets, aqueous solutions, syrups, emulsions, suspensions, solutions, soft gels, dispersions and the like.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered orally to the subject in the form of an orally disintegrating tablet.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in the form of an intramuscular injection.
  • a method of treating mania in a subject in need thereof without also inducing significant sedation comprising administering intramuscularly a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis wherein said subject is in a non-agitated state.
  • mania is associated with depression.
  • the mania is associated with bipolar disorder.
  • mania is associated with other neuropsychiatric disorders.
  • dexmedetomidine or a pharmaceutically acceptable salt is administered daily for at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or at least one year.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered intramuscularly at a dose of about 10 pg to about 200 pg, e.g. about 20 pg to about 190 pg, about 30 pg to about 190 pg, about 40 pg to about 190 pg, about 50 pg to about 190 pg, about 60 pg to about 190 pg, about 70 pg to about 190 pg, about 80 pg to about 190 pg, about 90 pg to about 190 pg, about 100 pg to about 190 pg, about 110 pg to about 190 pg, about 120 pg to about 190 pg, about 130 pg to about 190 pg, about 140 pg to about 190 pg, about 150 pg to about 190 pg, about 160 pg to about 190 pg, about 170 pg to about
  • a method of treating an acute manic episode in a human subject with the diseased condition, without also inducing significant sedation comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered intramuscularly at a dose of about 10 pg to about 300 pg, (e.g. about 120 pg to about 190 pg).
  • the diseased condition is neuropsychiatric disorder such as bipolar disorder (such as bipolar I disorder and bipolar II disorder).
  • the neuropsychiatric disorder may be delirium, depression, schizophrenia; optionally the dementia or mood disorder may be in a subj ect with maj or depression or another related neuropsychiatric disorder.
  • dexmedetomidine is administered to the subject on a daily basis. In embodiments, dexmedetomidine is administered to the subject on daily basis for one to six times a day.
  • the treatment is effective without causing significant sedation. In embodiments, the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the subject is agitated. In embodiments, the subject is in a non-agitated state.
  • a method of treating a recurring manic episode in a human subject with the diseased condition, without also inducing significant sedation comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered intramuscularly at a dose of about 10 pg to about 200 pg, (e.g. about 120 pg to about 190 pg).
  • the diseased condition is neuropsychiatric disorder such as bipolar disorder (such as bipolar I disorder and bipolar II disorder).
  • the neuropsychiatric disorder may be delirium, depression, schizophrenia; optionally the dementia or mood disorder may be in a subj ect with maj or depression or another related neuropsychiatric disorder.
  • dexmedetomidine is administered to the subject on a daily basis. In embodiments, dexmedetomidine is administered to the subject on daily basis for one to six times a day.
  • the treatment is effective without causing significant sedation. In embodiments, the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the subject is agitated. In embodiments, the subject is in a non-agitated state.
  • the present disclosure provides an intramuscular injectable composition for treating mania in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • YMRS Young Mania Rating Scale
  • the YMRS is an 11-item, clinician-administered rating scale to assess the severity of manic symptoms before, during and after treatment. There are four items that are graded on a 0 to 8 scale (irritability, speech, thought content, and disruptive/aggressive behavior), while the remaining seven items are graded on a 0 to 4 scale. A score of 0 indicates the behavior is absent, whereas a score of 4 or 8 indicates the behavior is present and severe.
  • the present disclosure also provides a method of achieving a YMRS score reduction in mania for a sustained period of time in a subject with bipolar disorder or other neurological disorders (e.g. neuropsychiatric disorders, neurodegenerative disorders or so on) comprising administering to the subject a pharmaceutical composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose of about 40 pg to about 180 pg on a daily basis for at least one month.
  • the mean YMRS score reduction is at least about 30%.
  • the mean YMRS score reduction is about 35%.
  • the mean YMRS total score reduction is about 40%.
  • YMRS score reduction is about 45%.
  • YMRS score reduction is about 50% from baseline. In embodiments, YMRS score reduction is more than 50%. In embodiments, the dosage may be administered for at least 2 weeks. In embodiments, the administration is followed by conventional mood stabilizer, antipsychotic or standard of care.
  • the dosage of dexmedetomidine or a pharmaceutically acceptable salt thereof may be administered twice a day.
  • the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered at a dose of about 30 pg to about 90 pg during daytime (e.g., 30 pg, 45 pg, 60 pg, or 90 pg) and about 120 pg to about 180 pg during night-time (e.g., 120 pg or 180 pg).
  • the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered at a dose of about 30 pg to about 90 pg during daytime and 30 pg to about 90 pg during night-time. In embodiments, the dosages of dexmedetomidine or a pharmaceutically acceptable salt thereof are administered twice a day at a dose of about 120 pg to about 180 pg during daytime and about 30 pg to about 90 pg during nighttime.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered as 60 pg per unit dose twice a day to a total dose of 120 pg. For example, a 60 pg unit dose is taken in the morning and another 60 pg unit dose is taken in the evening or night-time.
  • the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at night-time. In embodiments, the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at day-time. In embodiments, the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at night time and day-time.
  • the composition comprises dexmedetomidine hydrochloride.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of about 120 pg on a daily basis for at least one month.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of about 180 pg on a daily basis for at least one month.
  • the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a night-time once a day.
  • the sustained period is about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours.
  • a method of treating psychosis associated with a diseased condition in a subject in need thereof comprising administering oromucosally (for example, sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the psychosis is associated with a neuropsychiatric disorder selected from the group consisting of schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorder optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • a neuropsychiatric disorder selected from the group consisting of schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorder optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • the psychosis is associated with diseased condition such as substance abuse disorders (e.g, alcohol, opioid and other substance withdrawal).
  • substance abuse disorders e.g, alcohol, opioid and other substance withdrawal.
  • the subject is in an agitated state. In embodiments, the subject is in a non-agitated state.
  • a method of treating psychosis associated with neuropsychiatric disorders in a subject in need thereof comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis for at least one month wherein said subject is in a non-agitated state.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered for at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or at least one year.
  • psychosis is associated with schizophrenia. In embodiments, psychosis is associated with bipolar disorder. In embodiments, psychosis is associated with schizoaffective disorder. In embodiments, psychosis is associated with depression. In embodiments, psychosis is associated with dementia. In embodiments, psychosis is associated with Parkinson’s disease.
  • a method of treating psychosis associated with neurodegenerative disorders in a subject in need thereof comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis for at least one month.
  • dexmedetomidine or a pharmaceutically acceptable salt is administered for at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or at least one year.
  • the psychosis is acute. In embodiments, the psychosis is chronic. In embodiments, the psychosis is a single episode. In embodiments, the psychosis is recurring or includes recurrent episodes. In embodiments, the acute psychosis is associated with acute psychotic episodes and/or mixed episodes.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of about 2 pg to about 405 pg, such as about 120 pg to about 270 pg, or at a dose of about 180 pg to about 405 pg, such as about 180 pg to about 270 pg, including administering doses of about 120 pg or about 180 pg, to treat psychosis in a human subject.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered oromucosally at a dose of about 2 pg to about 300 pg, such as about 10 pg to about 250 pg, or at a dose of about 10 pg to about 200 pg, such as about 30 pg to about 180 pg, including administering doses of about 30 pg, 60 pg, 90 pg, 120 pg or about 180 pg, to treat psychosis in a human subject, without also inducing significant sedation.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered oromucosally at a dose of about 2 pg to about 300 pg, such as about 10 pg to about 250 pg, or at a dose of about 10 pg to about 200 pg, such as about 30 pg to about 180 pg, including administering doses of about 30 pg, 60 pg, 90 pg, 120 pg or about 180 pg, to treat psychosis in a human subject, without also inducing significant sedation wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered on daily basis for at least one month.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered once a day. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at night-time once a day. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of 120 pg at night-time on daily basis (e.g. once a day). In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of 180 pg at night-time once a day. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is also administered at day-time on an as needed basis. In embodiments, dexmedetomidine or a pharmaceutically acceptable administered on an as-needed basis is at a different dose than the night-time dose.
  • the present disclosure provides methods of treating psychosis in a human subject with diseased condition, without also inducing significant sedation, comprising administering oromucosally (e.g. sublingually or buccally) from about 30 pg to about 300 pg of dexmedetomidine or a pharmaceutically acceptable salt thereof on a daily basis for at least one month.
  • the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a night-time.
  • the present disclosure provides a method of treating psychosis in a human subject with the diseased condition, without also inducing significant sedation, comprising administering oromucosally (e.g. sublingually or buccally) dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. the hydrochloride salt) as a single dose of about 30 pg, about 60 pg, about 90 pg, about 120 pg, about 180 pg or about 240 pg.
  • the treatment is effective without causing clinically significant cardiovascular effects.
  • the present disclosure provides a method of treating psychosis associated with the diseased condition in a human subject, comprising administering oromucosally a film composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. hydrochloride salt) as a single dose of 120 pg or 180 pg.
  • an additional dose e.g. 90 pg or 60 pg
  • a suitable period of time e.g. 2-hours
  • the treatment is effective without causing significant sedation.
  • the present disclosure provides a method of treating psychosis in a human subject with the diseased condition, without also inducing significant sedation, comprising administering oromucosally (e.g. sublingually or buccally) dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. the hydrochloride salt) as a single dose of about 30 pg, about 60 pg, about 90 pg, about 120 pg or about 180 pg on daily basis at night-time.
  • the treatment is effective without causing clinically significant cardiovascular effects.
  • wherein said subject is in a non-agitated state.
  • the present disclosure provides a method of treating acute psychotic episode associated with the diseased condition in a human subject, comprising oromucosally administering a film composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. hydrochloride salt) as a single dose of 30 pg, 60 pg, 90 pg, 120 pg or 180 pg.
  • a pharmaceutically acceptable salt thereof e.g. hydrochloride salt
  • an additional dose e.g. 30 pg, 60 pg or 90 pg,
  • a suitable period of time e.g. 2-hours
  • the present disclosure provides a method of treating chronic psychosis associated with the diseased condition in a human subject, comprising oromucosally administering a film composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. hydrochloride salt) as a single dose of 30 pg, 60 pg, 90 pg, 120 pg, 180 pg or 240 pg.
  • an additional dose e.g. 30 pg, 60 pg or 90 pg
  • a suitable period of time e.g. 2-hours
  • said subject is in a non-agitated state.
  • the disclosure provides methods of treating psychosis in a schizophrenia patient in need thereof, comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject wherein said subject is in a non-agitated state.
  • the present disclosure provides an oromucosal film composition for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, one or more water-soluble polymers and one or more pharmaceutically acceptable excipients and/or carriers.
  • the film is mucoadhesive.
  • the film has a disintegration time of about 10 seconds to about 60 seconds.
  • the present compositions are in the form of an oromucosal tablet for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the present compositions are in the form of an oromucosal spray formulation for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the present compositions are in the form of an oromucosal drop formulation for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • compositions are in the form of an oromucosal gel formulation for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the disclosure provides methods of treating psychosis in a schizophrenia patient in need thereof, comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject wherein said subject is in a non-agitated state.
  • a method of treating psychosis associated with a diseased condition in a subject in need thereof comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • the treatment is effective without causing significant sedation.
  • the treatment is effective without experiencing clinically significant cardiovascular effects.
  • the psychosis is associated a neuropsychiatric disorder selected from the group consisting of schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorders, optionally the dementia or mood disorder in a subject with a major depressive episode, in major mood disorder or another related neuropsychiatric disorder.
  • the psychosis is associated with diseased conditions such as substance abuse disorders (e.g, alcohol, opioid and other substance withdrawal). In embodiments, the psychosis may not be associated with substance abuse disorders.
  • the subject is in an agitated state. In embodiments, the subject is in a non-agitated state.
  • a method of treating psychosis associated with neuropsychiatric disorders in a subject in need thereof comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis for at least one month wherein said subject is in a non-agitated state.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered for at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or at least one year.
  • psychosis is associated with schizophrenia.
  • psychosis is associated with bipolar disorder.
  • psychosis is associated with schizoaffective disorder.
  • psychosis is associated with depression.
  • psychosis is associated with dementia.
  • a method of treating psychosis associated with neurodegenerative disorders in a subject in need thereof comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis for at least one month.
  • dexmedetomidine or a pharmaceutically acceptable salt is administered for at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 12 months or at least one year.
  • the psychosis is acute. In embodiments, the psychosis is chronic. In embodiments, the psychosis is a single episode. In embodiments, the psychosis is recurring or includes recurrent episodes. In embodiments, the acute psychosis is associated with acute and/or mixed episodes.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered intramuscularly at a dose of about 10 pg to about 200 pg to treat psychosis in a human subject, without also inducing significant sedation.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered on daily basis for at least one month.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is administered once a day.
  • dexmedetomidine or a pharmaceutically acceptable salt thereof is also administered at day-time on as needed basis.
  • dexmedetomidine or a pharmaceutically acceptable is administered on as-needed basis at a different dose than the nighttime dose.
  • the present disclosure provides methods of treating psychosis in a human subject with diseased condition, without also inducing significant sedation, comprising administering intramuscularly from about 10 pg to about 200 pg of dexmedetomidine or a pharmaceutically acceptable salt thereof on a daily basis for at least one month.
  • the present disclosure provides a method of treating psychosis in a human subject with the diseased condition, without also inducing significant sedation, comprising administering intramuscularly dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. the hydrochloride salt) as a single dose of about 10 pg to about 200 pg .
  • the treatment is effective without causing clinically significant cardiovascular effects.
  • the present disclosure provides a method of treating acute psychotic episode associated with the diseased condition in a human subject, comprising administering an intramuscular composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. hydrochloride salt) as a single dose of 10 pg , about 20 pg, about 30 pg, about 40 pg, about 60 pg, about 90 pg, about 120 pg, about 140 pg, about 160 pg, about 180 pg, about 200 pg or about 240 pg.
  • an intramuscular composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. hydrochloride salt) as a single dose of 10 pg , about 20 pg, about 30 pg, about 40 pg, about 60 pg, about 90 pg, about 120 pg, about 140 pg, about 160 pg, about 180 pg, about 200 pg or about 240 pg
  • the present disclosure provides a method of treating chronic psychosis associated with the diseased condition in a human subject, comprising intramuscularly administering a composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof (e.g. hydrochloride salt) as a single dose of 10 pg , about 20 pg, about 30 pg, about 40 pg, about 60 pg, about 90 pg, about 120 pg, about 140 pg, about 160 pg, about 180 pg or about 200 pg.
  • said subject is in a non-agitated state.
  • the present compositions are in the form of an intramuscular composition for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the present compositions are in the form of an oral composition for treating psychosis in a subject in need thereof, comprising an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers.
  • the oral compositions are in the form of oral tablets, orally disintegrating tablets (ODTs), effervescent tablets, capsules, pellets, pills, lozenges or troches, powders, dispersible granules, sachets, aqueous solutions, syrups, emulsions, suspensions, solutions, soft gels, dispersions and the like
  • ODTs Positive and Negative Syndrome Scale
  • PANSS Positive and Negative Syndrome Scale
  • the present disclosure provides methods of achieving a PANSS score reduction in psychosis for a sustained period of time in a subject with schizophrenia or other neurological disorders (e.g. neuropsychiatric disorders, neurodegenerative disorders or so on) comprising administering to the subject a pharmaceutical composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose of about 120 pg to about 180 pg on a daily basis for at least one month wherein said subject is in a non-agitated state.
  • the PANSS score reduction is at least about 20% to about 50% from baseline score prior to treatment with dexmedetomidine.
  • the PANSS score reduction is about 25% from baseline score.
  • the PANSS total score reduction is about 30% from baseline score. In embodiments, the PANSS total score reduction is about 35% points from baseline score. In embodiments, the PANSS total score reduction is about 40% points from baseline score. In embodiments, the PANSS total score reduction is about 45% points from baseline score. In embodiments, the PANSS total score reduction is about 50% points from baseline score.
  • the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a night-time.
  • the composition comprises dexmedetomidine hydrochloride. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of about 120 pg on a daily basis for at least one month.
  • the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a night-time. In embodiments, dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of about 180 pg on a daily basis for at least one month. In embodiments, the dose of dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a night-time.
  • the sustained period is about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours.
  • the dose may be administered one or more times a day.
  • the doses can be administered daily for longer period of time for at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, at least about 30 days, at least about 2 months, at least about 3 months, at least 4 months, at least 5 months, at least 6 months or so on.
  • a method of treating anxiety in a subject in need thereof comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject wherein said subject is in a non-agitated state.
  • the subject does not experience agitation.
  • agitation and anxiety can present differently. For example, a person that is agitated is quick to frustration or anger, often feeling bothered. Agitation is characterized by feeling of restlessness that manifest in an outward, physical manner via certain behaviors, such as pacing, verbalizations, and fidgeting.
  • anxiety may be defined as subjective experience of nervousness, worry, apprehension or restlessness, ranging from excessive concern about the present or future to feelings of panic.
  • agitation often manifests with a more physical component that can be seen by an observer.
  • the disclosure provides methods of treating anxiety in a schizophrenia patient in need thereof, comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • the disclosure provides methods of treating anxiety in a schizophrenia patient in need thereof, comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • the present disclosure provides methods as disclosed herein, wherein the methods comprises one or more additional therapeutic agents.
  • Such combination therapy may be particularly useful in the treatment of mania in various diseased conditions.
  • the combination therapy may be useful in the treatment of psychosis in various diseased conditions.
  • antidepressants such as selective serotonin reuptake inhibitors (SSRIs) that include sertraline (Zoloft), fluoxetine (Prozac, Sarafem), citalopram (Celexa); escitalopram (Lexapro), paroxetine (Paxil, Pexeva, Brisdelle), fluvoxamine (Luvox); serotonin and norepinephrine reuptake inhibitors (SNRIs) such as desvenlafaxine (Pristiq, Khedezla), duloxetine (Cymbalta), levomilnacipran (Fetzima), venlafaxine (Effexor XR); tricyclic antidepressants such as amitriptyline, amoxapine, clomipramine (Anafranil), desipramine (Norpramin), doxepin, imipramine (Tofranil), nortriptyline (Pamelor
  • SSRIs selective seroton
  • the present disclosure provides a film as disclosed herein, wherein the film comprises dexmedetomidine or a pharmaceutically acceptable salt thereof together with one or more additional therapeutic agents.
  • the drug combinations herein may be included in a monolithic film of the present disclosure or a micro-deposition film of the present disclosure. If in a monolithic film, the present disclosure provides for the presence of all drugs in a single matrix film layer. The drugs may also be present in separate monolithic films which are then combined to provide a multi-layer film.
  • the drugs are included in a micro-deposition film of this disclosure.
  • individual drug compositions may be added as discrete droplets to the surface of the film substrate (i.e. placebo film) according to the general process used and described herein to add the dexmedetomidine composition to a film substrate.
  • the droplets may be added in any pattern to suit the desired unit dose requirements.
  • the droplets may each include a colorant which may be the same or different for each drug composition. It may be convenient to use different colors to distinguish the different drugs on the surface of the film substrate.
  • the present disclosure provides an intramuscular injectable formulation as disclosed herein, wherein the formulation comprises dexmedetomidine or a pharmaceutically acceptable salt thereof together with one or more additional therapeutic agents.
  • both dexmedetomidine and additional active agent(s) are present as part of a single pharmaceutical composition for administration to the subject.
  • the active agents are present in separate pharmaceutical compositions, e.g. for concurrent and/or sequential administration to the subject.
  • Embodiment 1 A method of treating mania in a subject in need thereof, comprising administering oromucosally a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis wherein said subject is in a non-agitated state.
  • Embodiment 2 A method of treating psychosis in a subject in need thereof, comprising oromucosally administering a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis wherein said subject is in a non-agitated state.
  • Embodiment 3 A method of treating mania in a subject in need thereof, comprising administering intramuscularly a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis wherein said subject is in a non-agitated state.
  • Embodiment 4 A method of treating psychosis in a subject in need thereof, comprising administering intramuscularly a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject on a daily basis wherein said subject is in a non-agitated state.
  • Embodiment 5 The method of embodiments 1 to 4, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is dexmedetomidine hydrochloride.
  • Embodiment 6 The method according to embodiments 1 to 5, wherein the therapeutically effective amount of dexmedetomidine hydrochloride is about 2 pg to about 300 pg.
  • Embodiment 7 The method according to embodiments 1 to 5, wherein the therapeutically effective amount of dexmedetomidine hydrochloride is about 10 pg to about 200 pg.
  • Embodiment 8 The method according to embodiments 1 to 5, wherein the therapeutically effective amount of dexmedetomidine hydrochloride is about 30 pg to about 180 pg.
  • Embodiment 9 The method according to embodiment 1 or embodiment 3, wherein the mania is associated with neuropsychiatric disorder selected from the group comprising bipolar illness such as bipolar disorder (e.g. bipolar I disorder and bipolar II disorder), optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • bipolar illness such as bipolar disorder (e.g. bipolar I disorder and bipolar II disorder)
  • the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder e.g. bipolar I disorder and bipolar II disorder
  • Embodiment 10 The method according to embodiment 2 or embodiment 4, wherein the psychosis is associated with neuropsychiatric disorder selected from the group comprising schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorder (e.g. bipolar I disorder and bipolar II disorder), optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • neuropsychiatric disorder selected from the group comprising schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorder (e.g. bipolar I disorder and bipolar II disorder), optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • Embodiment 11 The method according to embodiment 2 or embodiment 4, wherein the psychosis is associated with substance abuse withdrawal (e.g. alcohol, opioid or other substance abuse withdrawal).
  • substance abuse withdrawal e.g. alcohol, opioid or other substance abuse withdrawal.
  • Embodiment 12 The method according to any one of embodiments 1, 3, 5 to 9, wherein the subjects suffers from episodes of acute mania, recurring mania, or both.
  • Embodiment 13 The method according to any one of embodiments 1, 3, 5 to 9, wherein the subjects suffer from single episode of mania.
  • Embodiment 14 The method according to any one of embodiments 1, 3, 5 to 9, wherein the subjects suffer from recurrent episodes of mania.
  • Embodiment 15 The method according to any one of embodiments 1, 3, 5 to 9, wherein the mania is mild or severe.
  • Embodiment 16 The method according to any of embodiments 1, 3, 5 to 9, wherein the reduction in mania is measured using YMRS scale.
  • Embodiment 17 A method of achieving YMRS score reduction in mania for a sustained period of time in a subject with bipolar disorder or other neuropsychiatric disorders, comprising administering to the subject a pharmaceutical composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose of about 120 pg to about 180 pg on a daily basis for at least one month, wherein the YMRS score reduction is at least about 30% to about 50%.
  • Embodiment 18 The method according to any one of embodiments 2, 4, 10 and 11, wherein subject suffers from episodes of acute psychosis, chronic psychosis, or both.
  • Embodiment 19 The method according to any one of embodiments 2, 4, 10 and H, wherein subject suffers from single episode or mixed episodes of psychosis.
  • Embodiment 20 The method according to any one of embodiments 2, 4, 10 and H, wherein subject suffers from recurrent episodes of psychosis.
  • Embodiment 21 The method according to any one of embodiments 2, 4, 10 and H, wherein severity of psychosis in the subject is assessed using PANSS scale.
  • Embodiment 22 A method of achieving a PANSS score reduction in psychosis for a sustained period of time in a subject with schizophrenia or other neurological disorders (e.g. neuropsychiatric disorders, neurodegenerative disorders or so on) comprising administering to the subject a pharmaceutical composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose of about 120 pg to about 180 pg on a daily basis for at least one month wherein said subject is in a non-agitated state and the PANSS score reduction is at least about 20% to about 50% from baseline score.
  • schizophrenia or other neurological disorders e.g. neuropsychiatric disorders, neurodegenerative disorders or so on
  • a pharmaceutical composition comprising dexmedetomidine or a pharmaceutically acceptable salt thereof at a dose of about 120 pg to about 180 pg on a daily basis for at least one month wherein said subject is in a non-agitated state and the PANSS score reduction is at least about 20% to about 50% from baseline score.
  • Embodiment 23 The method according to embodiment 17 and 22, wherein the sustained period is about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, or about 24 hours.
  • Embodiment 24 The method according to any one of embodiments 1 to 9 and 12, wherein the subject suffers from anxiety with depression, hypomania, dysphoric mania, mixed mania, depressive episodes or combination thereof.
  • Embodiment 25 The method according to embodiment 1 to 4, wherein the subject is a human.
  • Embodiment 26 The method according to embodiment 1 to 4, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered oromucosally (e,g, sublingually or buccally).
  • Embodiment 27 The method according to embodiment 26, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered sublingually in the form of a tablet, film, spray, gel or drops.
  • Embodiment 28 The method according to embodiment 27, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in the form of a film.
  • Embodiment 29 The method according to embodiment 27, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in the form of a spray.
  • Embodiment 30 The method according to embodiment 27, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in the form of a tablet.
  • Embodiment 31 The method according to embodiment 27, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in the form of a gel.
  • Embodiment 32 The method according to embodiment 27, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in the form of a drop.
  • Embodiment 33 The method according to embodiment 26, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered buccally in the form of a tablet, film, spray, gel or drops.
  • Embodiment 34 The method according to embodiment 33, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered in the form of a film.
  • Embodiment 35 The method according to embodiments 1 to 4, wherein the subject is treated without causing significant sedation.
  • Embodiment 36 The method according to embodiments 1 to 4, wherein the subject is treated without experiencing clinically significant cardiovascular effects.
  • Embodiment 37 The method according to embodiments 1 to 4, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered one to six times a day.
  • Embodiment 38 The method according to embodiment 37, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered once daily.
  • Embodiment 39 The method according to embodiment 1 to 4, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered as a single dose.
  • Embodiment 40 The method according to embodiments 1 to 4, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered for at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least
  • 28 days at least 29 days, at least 30 days, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months or at least 1 year.
  • Embodiment 41 The method according to the preceding embodiments, wherein dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at night-time once a day.
  • Embodiment 42 The method according to embodiment 41, further comprising administering dexmedetomidine or a pharmaceutically acceptable salt thereof in the day-time on an as-needed basis.
  • Embodiment 43 The method of embodiment 42, wherein the dexmedetomidine or a pharmaceutically acceptable administered on an as-needed basis is at a different dose than the night-time dose.
  • Embodiment 44 The method according to embodiment 43, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of 120 pg at night-time once a day.
  • Embodiment 45 The method according to embodiment 43, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered at a dose of 180 pg at night-time once a day.
  • Embodiment 46 The method according to any of preceding embodiments, wherein an additional dose of dexmedetomidine or a pharmaceutically acceptable salt thereof may be taken after a suitable period of time (e.g. 2-hours) in the event of persistent or recurrent mania on a daily basis for one to six times a day
  • a suitable period of time e.g. 2-hours
  • Embodiment 47 The method according to embodiments 1 to 4, wherein the subject is agitated or non-agitated.
  • Embodiment 48 A pharmaceutical composition for the treatment of mania in a subject in need thereof, comprising effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers wherein said composition is administered on a daily basis wherein said subject is in a non-agitated state.
  • Embodiment 49 A pharmaceutical composition for the treatment of psychosis in a subject in need thereof, comprising effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable excipients and/or carriers wherein said composition is administered on a daily basis wherein said subject is in a nonagitated state.
  • Embodiment 50 The pharmaceutical composition according to embodiment 48 or embodiment 49, wherein dexmedetomidine is present as dexmedetomidine hydrochloride.
  • Embodiment 51 The pharmaceutical composition according to embodiment 48 or embodiment 49, wherein the composition is formulated for oromucosal (sublingual or buccal) administration.
  • Embodiment 52 The pharmaceutical composition according to embodiment 51, wherein the composition is formulated for sublingual administration.
  • Embodiment 53 The pharmaceutical composition according to embodiment 52, wherein the composition is formulated for sublingual administration in the form of a tablet, film, spray, gel or drops.
  • Embodiment 54 The pharmaceutical composition according to embodiment 51, wherein the composition is formulated for buccal administration in the form of a film, patch or tablet.
  • Embodiment 55 The pharmaceutical composition according to embodiment 53 or embodiment 54, wherein the composition is a film.
  • Embodiment 56 The pharmaceutical composition according to embodiment 48, wherein the mania is associated with a neuropsychiatric disorder selected from the group comprising bipolar illness such as bipolar disorder (e.g. bipolar I disorder and bipolar II disorder), optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • a neuropsychiatric disorder selected from the group comprising bipolar illness such as bipolar disorder (e.g. bipolar I disorder and bipolar II disorder), optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • Embodiment 57 The pharmaceutical composition according to embodiment 49, wherein the psychosis is associated with a neuropsychiatric disorder selected from the group comprising schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorder (e.g. bipolar I disorder and bipolar II disorder) optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • a neuropsychiatric disorder selected from the group comprising schizophrenia, schizoaffective disorder, depression, dementia and bipolar disorder (e.g. bipolar I disorder and bipolar II disorder) optionally the dementia or mood disorder in a subject with major depressive episode or another related neuropsychiatric disorder.
  • Embodiment 58 The method according to embodiment 49, wherein the psychosis is associated with substance abuse withdrawal (e.g. alcohol, opioid or other substance abuse withdrawal).
  • substance abuse withdrawal e.g. alcohol, opioid or other substance abuse withdrawal.
  • Embodiment 59 The methods/pharmaceutical composition according to any of preceding embodiments, wherein the dexmedetomidine or a pharmaceutically acceptable salt thereof is administered by intramuscular route.
  • Embodiment 60 A sublingual film composition for treating mania , comprising: i. a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof; ii. one or more water-soluble polymers and iii. one or more pharmaceutically acceptable excipients and/or carriers. wherein said composition is administered on a daily basis and said subject is in a non-agitated state.
  • Embodiment 61 A sublingual film composition for treating psychosis, comprising: i. a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof; ii. one or more water-soluble polymers and iii. one or more pharmaceutically acceptable excipients and/or carriers. wherein said composition is administered on a daily basis and said subject is in a non-agitated state.
  • Embodiment 62 The film composition according to embodiment 60 or embodiment 61, wherein dexmedetomidine is present as dexmedetomidine hydrochloride.
  • Embodiment 63 The film composition according to embodiment 60 or embodiment 61, in the form of dosage unit, wherein amount of dexmedetomidine or a pharmaceutically acceptable salt thereof present per unit is about 0.5 pg to about 300 pg.
  • Embodiment 64 The film composition according to embodiment 63, wherein said dosage is about 2 pg to about 200 pg.
  • Embodiment 65 The film composition according to embodiment 60 or embodiment 61, wherein the film comprises dexmedetomidine or a pharmaceutically acceptable salt thereof together with one or more additional therapeutic agents.
  • Embodiment 66 The film composition according to embodiment 65, wherein said additional therapeutic agents are administered simultaneously, sequentially or separated by an appropriate period of time.
  • Embodiment 67 A kit comprising (a) a therapeutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof in one or more unit dosages; (b) a finished container containing said unit doses; and (c) a label instructions stating that said dosages can be administered to treat mania and/or psychosis wherein said subject is in a non-agitated state.
  • Embodiment 68 The method according to embodiments 3 to 5 wherein the therapeutically effective amount of dexmedetomidine hydrochloride is about 2 pg to about 200 pg.
  • Embodiment 69 The method according to embodiments 3 to 5, wherein the therapeutically effective amount of dexmedetomidine hydrochloride is about 10 pg to about 180 pg.
  • Embodiment 70 The method according to embodiments 3 to 5, wherein the therapeutically effective amount of dexmedetomidine hydrochloride is about 30 pg to about lOOpg.
  • Embodiment 71 The method or the pharmaceutical composition according to any of preceding embodiments, wherein the subject is agitated.
  • Embodiment 72 A method of treating anxiety in need thereof, comprising administering oromucosally (sublingually or buccally) an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • Embodiment 73 A method of treating anxiety in need thereof, comprising administering intramuscularly an effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof to the subject.
  • Embodiment 74 The method according to embodiment 72 or embodiment 73, wherein the subject is suffering from schizophrenia.
  • Example 1 Dexmedetomidine sublingual film formulation
  • Table 6 Dexmedetomidine deposited on the surface of a polymer matrix film composition
  • Polymer mixture Polyethylene oxide and fast emerald green shade were mixed in water for at least 180 minutes at about 1400 rpm to about 2000 rpm. Sucralose, hydroxypropyl cellulose (molecular weight 140K), hydroxypropyl cellulose, HPC-SSL (molecular weight 40K) and hydroxypropyl cellulose (molecular weight 370K) were added and mixed for at least 120 minutes at about 1600 rpm to 2000 rpm. Peppermint Oil was added to water and the resultant dispersion was then added to the polymer mixture and mixed for at least 30 minutes. The resultant mixture was further mixed under vacuum (248 torr) for at least for 30 minutes at a speed of 350 rpm and at temperature of 22.9°C.
  • Sucralose, hydroxypropyl cellulose (molecular weight 140K), hydroxypropyl cellulose, HPC-SSL (molecular weight 40K) and hydroxypropyl cellulose (molecular weight 370K) were added and mixed for at least 120 minutes
  • Coating station A roll was placed on an unwind stand and the leading edge was thread through guide bars and coating bars. The silicone-coated side of the liner was placed faced up. A gap of 40 millimeters was maintained between the coating bars. The oven set point was adjusted to 70oC and the final drying temperature was adjusted to 85°C.
  • Coating/drying process The polymer mixture was poured onto the liner between the guide bars and the coating bars. The liner was pulled slowly through the coating bar at a constant speed by hand until no liquid was remained on the coating bars. The liner was cut to approximately 12- inch length hand sheets using a safety knife. Each hand sheet was placed on a drying board and was tapped on the corners to prevent curl during drying. The hand sheets were dried in the oven until the moisture content was less than 5% (approximately 30 minutes) and then removed from the drying board. The coating weights were checked against the acceptance criteria, and if met, the hand sheets were then stacked and placed in a 34 inch x 40 inch foil bag that was lined with PET release liner.
  • FDC blue was dissolved in ethyl alcohol for at least 180 minutes.
  • Dexmedetomidine hydrochloride was added to the ethyl alcohol solution with continuous stirring for 10 minutes at about 400 rpm to about 800 rpm.
  • Hydroxypropyl cellulose (40K) and hydroxypropyl cellulose (140K) were added to the mixture, and stirred for at least 30 minutes until all the materials were dissolved.
  • the deposition solution obtained in Step (B) above was filled into a pipette to the required volume (determined according to the specific drug product strength of the final product).
  • the film was initially die cut in individual units with dimensions of 22 mm x 8.8 mm containing a single deposit of the drug-containing composition.
  • the die cut micro-deposited matrixes were then dried in an oven for 70°C for 10 minutes and further die cut into 10 units with each unit containing a single deposit of the drug-containing composition.
  • Table 7 Dexmedetomidine deposited on the surface of a polymer matrix film composition
  • Example 3 Efficacy and Safety of dexmedetomidine hydrochloride sublingual film in subjects with bipolar mania.
  • Subjects were randomized to 180pg dexmedetomidine hydrochloride sublingual film or 120pg dexmedetomidine hydrochloride sublingual film or matching placebo. Efficacy and safety assessments were conducted periodically before and after dosing.
  • Placebo was chosen as a comparator to more accurately assess efficacy as well as safety and tolerability.
  • the randomized, double-blind parallel-group design ensures the sponsor, all subjects, and study staff involved were shielded from treatment assignment and outcomes and therefore minimized any potential bias.
  • the randomization ratio provided an additional element that ensured blinding by decreasing the odds of guessing treatment arms.
  • Female participants if of child-bearing potential and sexually active, and male participants, if sexually active with a partner of child-bearing potential, who agreed to use a medically acceptable and effective birth control method throughout the study and for one week following the end of the study.
  • Medically acceptable methods of contraception that might be used by the participant and/or his/her partner include abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine device (IUD), condom with foam or spermicide, vaginal spermicidal suppository, surgical sterilization, and progestin implant or injection.
  • Prohibited methods include: the rhythm method, withdrawal, condoms alone, or diaphragm alone.
  • Dexmedetomidine hydrochloride was in a film formulation for sublingual (SL) administration. Dosing delivered 180pg or 120pg of dexmedetomidine hydrochloride sublingually. The product was a small, solid-dose film formulation, approximately 193.6 mm 2 in area and 0.7 mm thick, that dissolved in the oromucosal space within about 1-3 minutes.
  • Pre-dose assessments had a window of 60 minutes prior to dose with the exception of PEC and ACES which were performed within 15 minutes of dosing (15 to 0 min). All post-dose assessments had a window of -5/+15 minutes through the 1.5 hour assessments, -5Z+25 minutes for the 2 hour assessments (with the exception of the PEC which had a +/-5 minute window) and ⁇ 30 minutes for the 4, 6 and 8 hour assessments and YMRS could be performed at any time.
  • Safety Labs included chemistry, hematology, urinalysis, UDS (local lab, only conducted at screening), alcohol breathalyzer (only conducted at screening), and urine pregnancy (only conducted at screening) Screening/enrollment labs: local labs drawn within 7 days prior to screening might suffice with the exception of urine drug screen. If results not available on the same day, a ‘desktop' or non-CLIA test might be performed; to confirm, results from a CLIA -certified laboratory’ should be recorded once available. Central Labs should be performed on Screening, Day’ 3 and Day 7.
  • ECG for pre-dose does not need to be repeated if screening ECG was conducted on the day of dosing. ECGs collected following treatment were performed prior to PK assessments.
  • PEC was performed at Screening, Pre-dose (within 15 min prior to dose) and at 10, 20, 30, 45 min; I, 1.5, 2, 4, 6, 8 and 24 hours post dose
  • the PCRS must be performed prior to PEC rating, when required.
  • ACES was performed at Pre-dose (within 15 min of dose), 2, 4 and 8 hrs post dose
  • CGI-Severity was performed at Screening and pre-dose.
  • CGI-Improvement was performed at 30 minutes, 1, 2 and 4 hours post dose.
  • PK blood samples were collected 1, 4, and 8 hr (while awake) after dose. A sample might not be collected if the Physician indicated in source documents that the patient was in a mental slate that was no! conducive to PK sample collection. Non-compliance or refusal of ail or arty PK draw was not exclusionary nor result in ET. Vital signs were to be done prior to PK sample draws, when performed at the same timepoints.
  • the investigator might chose to re-dose the patient after the 2 hour post-dose assessments are performed if the PEC change from baseline is ⁇ 40%. Patients could re-dosed after completing the 2 hour post first dose assessments. Repeat dosing administers half of a film. Patients could redosed twice in the 12 hour period post first dose. All assessments listed in this Schedule of Events al the 2 hour posi first dose limepoint should be repeated al 2 hours post every re-dose Assessment at 4, 6. or 8 hour post first dose that occur within 1 hour of a post re-dose assessment were not required to be performed
  • the YMRS is an 11 -item scale evaluating mania symptoms based on the patient’s subjective report of their clinical condition. It was used to characterize the patient population enrolled in the study.
  • Blood samples (4 ml) were collected per Table 8- Schedule of Events. For each subject, up to 3 blood samples (12 mL of blood) were collected during the study for PK analysis. In addition, approximately 30 mL of blood was collected at screening, approximately 15 mL of blood was collected at Day 3 Discharge, and approximately 15 mL of blood was collected at Day 7(+2) for clinical laboratory testing. The total volume of blood collected during the study was expected to be approximately 72 mL. For each subject, up to 3 blood samples (12 mL of blood) were collected during the study for PK analysis.
  • Plasma concentrations and concentration-time data for dexmedetomidine were used to calculate PK parameters; these data and results were reported separately. Details regarding the analyses of PK data were described in a separate PK SAP. The separate SAP for the PK analyses was prepared and finalized prior to database lock.
  • the primary efficacy endpoint of the study was the absolute change from baseline in the PEC total score at 120 min.
  • the intent to treat population was analyzed and consist of all patients who took any study medication and who had both baseline and at least 1 efficacy assessment after dosing.
  • Young Mania Rating Scale is an 1 litem scale evaluating mania symptoms based on the patie nt’s subjective report of their clinical condition.
  • Treatment Effect Least square mean (LSM) difference, standard error (SE), and 95% confidence i ntervals (Cis) between dexmedetomidine sublingual film and Placebo.
  • LSM Least square mean
  • SE standard error
  • Cis 95% confidence i ntervals
  • Dexmedetomidine sublingual film treatment significantly improved mania from baseline as measured by YMRS in bipolar disorder patients. As given in figure 1, the most robust effects were measured on motor activity, irritability, thought disorder, content, aggressive behavior and appearance. The treatment effect shows a decrease of 3.1 +/-0.7 SE for 180 ug and a decrease of 2.5 +/-0.7 SE for 120 ug. These data show that a YMRS reduction of about 2 to 3 is achieved (approximately 30% to 40% reduction). By removing the EC (excited component) items from the PANSS score, the effect of dexmedetomidine in nonagitated patients is identified. Here those data confirm that dexmedetomidine reduces mania in non-agitated patients.
  • Table 11 depicts that change in PANSS total minus PEC after sublingual administration of Dexmedetomidine thin film 120 and 180 pg.
  • EXAMPLE-5 Antipsychotic effect of Dexmedetomidine hydrochloride in mice using Smartcube system.
  • test drug By comparing the responses of animals to known drugs, the test drug can be categorized according to its function; for example, hallucinogen, anxiogenic, analgesic, cognitive enhancer, psychostimulant, mood stabilizer, high dose anti-psychotic, anti-psychotic, sedative/hypnotic, anxiolytic, high dose antidepressant, antidepressant.
  • SmartCube reference data used herein include anti-psychotics tested at several dose ranges. “Anti-psychotic” versus “high dose anti-psychotic” as indicated in the legend, reflects the notion that anti-psychotics reference data is dose-dependent. Anti-psychotics, when administered at higher doses, can engage additional receptor systems and thus affect mouse behavior differently.
  • Test groups were:
  • Test compounds were injected intraperitoneally (IP) for 15 min before animals were placed in SmartCube for assessment.
  • IP Intraperitonealy
  • NPS vehicle
  • Antipsychotic SmartCube classifies the mouse behaviour with test compound as similar to treatment with marketed anti-psychotics at therapeutically relevant doses.
  • High Dose Antipsychotic SmartCube classifies the mouse behaviour on test compound as similar to treatment with marketed anti-psychotics at doses that are considered as high therapeutically. High doses of anti-psychotics often cause sedation.
  • Antidepressant SmartCube classifies the mouse behaviour with test compound as similar to treatment with marketed anti-depressants at therapeutically relevant doses.
  • High dose Antidepressant SmartCube classifies the mouse behaviour on test compound as similar to treatment with marketed anti-depressants at doses that are considered high therapeutically.
  • Side Effects SmartCube classifies the mouse behaviour with test compound as similar to some of the side effects observed with high doses of therapeutically active compounds. Side effects can be for example severe sedation, impaired locomotion or seizures.
  • Dexmedetomidine has an antipsychotic signature in SmartCube.
  • Smart-Cube signatures from mice dosed (IP mg/kg; N 12 per group) with increasing concentrations of dexmedetomidine, an alpha2-adrenergic receptor agonist (Fig 2 (A).
  • Smart- Cube deep learning classifiers assign activity signatures by comparing phenotypic behavior of mice injected with dexmedetomidine to a library of reference data obtained with known compounds.
  • Smart-Cube dose-dependently classifies the dexmedetomidine group with increased accuracy (compared to vehicle) and assigns an antipsychotic signature. With higher doses of dexmedetomidine the antipsychotic signature changes to that of a high dose of anti-psychotic.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PCT/US2021/054171 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride Ceased WO2022076818A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202180069020.2A CN116615243A (zh) 2020-10-08 2021-10-08 使用右美托咪啶盐酸盐治疗躁郁症和精神病
MX2023003993A MX2023003993A (es) 2020-10-08 2021-10-08 Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina.
CA3195133A CA3195133A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
KR1020237013556A KR20230084186A (ko) 2020-10-08 2021-10-08 덱스메데토미딘 하이드로클로라이드를 사용한 양극성 장애 및 정신병의 치료
JP2023518752A JP2023545372A (ja) 2020-10-08 2021-10-08 デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
EP21878615.0A EP4225305A4 (en) 2020-10-08 2021-10-08 TREATMENT OF BIPOLAR DISEASES AND PSYCHOSES WITH DEXMEDETOMIDINE HYDROCHLORIDE
IL301971A IL301971A (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
US18/030,405 US20240024289A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
AU2021356687A AU2021356687A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
US63/089,135 2020-10-08

Publications (1)

Publication Number Publication Date
WO2022076818A1 true WO2022076818A1 (en) 2022-04-14

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/054171 Ceased WO2022076818A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Country Status (11)

Country Link
US (1) US20240024289A1 (https=)
EP (1) EP4225305A4 (https=)
JP (1) JP2023545372A (https=)
KR (1) KR20230084186A (https=)
CN (1) CN116615243A (https=)
AU (1) AU2021356687A1 (https=)
CA (1) CA3195133A1 (https=)
IL (1) IL301971A (https=)
MX (1) MX2023003993A (https=)
TW (1) TW202228682A (https=)
WO (1) WO2022076818A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786508B2 (en) 2016-12-31 2023-10-17 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11806429B2 (en) 2018-06-27 2023-11-07 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11890272B2 (en) 2019-07-19 2024-02-06 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11998528B1 (en) 2023-01-12 2024-06-04 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648106B2 (en) * 2012-01-04 2014-02-11 Hospira, Inc. Dexmedetomidine premix formulation
US20150098983A1 (en) * 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions
US20190365715A1 (en) * 2016-12-31 2019-12-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2906213T3 (en) * 2012-10-15 2018-02-19 Orion Corp VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY
EP3999058A4 (en) * 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648106B2 (en) * 2012-01-04 2014-02-11 Hospira, Inc. Dexmedetomidine premix formulation
US20150098983A1 (en) * 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Withdrawal Syndromes Using Non-Sedative Dexmedetomidine Transdermal Compositions
US20190365715A1 (en) * 2016-12-31 2019-12-05 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia (SERENITY I)", CLINICALTRIALS.GOV NCT04268303, 13 February 2020 (2020-02-13), pages 1 - 8, XP055931546, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04268303> [retrieved on 20211209] *
ANONYMOUS: "Young Mania Rating Scale", WIKIPEDIA, 28 December 2019 (2019-12-28), pages 1 - 2, XP055931551, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Young_Mania_Rating_Scale&oldid=932847993> [retrieved on 20211209] *
See also references of EP4225305A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786508B2 (en) 2016-12-31 2023-10-17 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11839604B2 (en) 2016-12-31 2023-12-12 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11931340B2 (en) 2016-12-31 2024-03-19 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
US11806429B2 (en) 2018-06-27 2023-11-07 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
US11890272B2 (en) 2019-07-19 2024-02-06 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11998529B2 (en) 2019-07-19 2024-06-04 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US12109196B2 (en) 2019-07-19 2024-10-08 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US11998528B1 (en) 2023-01-12 2024-06-04 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Also Published As

Publication number Publication date
JP2023545372A (ja) 2023-10-30
EP4225305A4 (en) 2024-10-23
AU2021356687A1 (en) 2023-06-15
CA3195133A1 (en) 2022-04-14
MX2023003993A (es) 2023-05-24
KR20230084186A (ko) 2023-06-12
EP4225305A1 (en) 2023-08-16
CN116615243A (zh) 2023-08-18
AU2021356687A9 (en) 2024-10-03
IL301971A (en) 2023-06-01
TW202228682A (zh) 2022-08-01
US20240024289A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
US11998529B2 (en) Non-sedating dexmedetomidine treatment regimens
US20240024289A1 (en) Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride
TW202019388A (zh) 含右美托咪啶(dexmedetomidine)之膜調配物及其製造方法
US12138247B2 (en) Non-sedating dexmedetomidine treatment regimens
US20250319069A1 (en) Methods for treating depressive states
JP2006508122A (ja) チザニジンの頬及び舌下デリバリーのための医薬組成物及び投与形態並びにチザニジンを舌下又は頬に投与する方法
WO2024263973A1 (en) Dexmedetomidine treatment regimens
EA045213B1 (ru) Пленочный состав, содержащий дексмедетомидин, и способ его получения
EA040771B1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21878615

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023518752

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 3195133

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202180069020.2

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 20237013556

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021878615

Country of ref document: EP

Effective date: 20230508

ENP Entry into the national phase

Ref document number: 2021356687

Country of ref document: AU

Date of ref document: 20211008

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 2021878615

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020237013556

Country of ref document: KR